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Lisa Fish, Ph.D.
The Rockefeller University 2016
Breast cancer is a prevalent disease. Metastatic disease accounts for the
majority of deaths from breast cancer, as patients with distant metastatic disease
have a much worse prognosis than those with localized disease. In order to
better understand why some breast cancers metastasize and others do not, it is
critical to identify and elucidate the determinants of breast cancer progression.
Post-transcriptional control of gene expression plays a central role in modulating
transcriptional output. The interactions between messenger RNA cis-regulatory
elements and trans-factors control coordinated gene expression states. Posttranscriptional regulatory programs that enhance metastatic capacity are selected
for during cancer progression. In this study, the RNA binding protein Muscleblindlike 1 (MBNL1) is identified as a novel suppressor of breast cancer metastasis.
MBNL1 loss-of-function contributes to the pathogenesis of myotonic dystrophy, a
human genetic disease, but has no reported role in tumorigenesis or cancer
progression. In this study, MBNL1 is identified as a suppressor of breast cancer
metastasis. MBNL1 was found to suppress metastasis of human breast cancer
cells in a xenograft mouse model. Additionally, MBNL1 transcript levels are
significantly correlated with metastasis-free survival of breast cancer patients.
MBNL1 depletion was also found to enhance the invasion and trans-endothelial
migration capacity of breast cancer cells. Identification of endogenous MBNL1
protein-RNA interactions in breast cancer cells was carried out using HITS-CLIP.
Transcriptome-wide analysis of MBNL1-dependent transcript stability and

MBNL1 HITS-CLIP data revealed that globally, transcripts directly bound by
MBNL1 are stabilized by MBNL1. Two transcripts, DBNL and TACC1, were
identified as transcripts that were bound by MBNL1 and also destabilized upon
MBNL1 depletion. Both DBNL and TACC1, when overexpressed in breast cancer
cells depleted of MBNL1, were found to reverse the pro-invasive and metastatic
colonization phenotypes observed upon MBNL1 depletion. Therefore, DBNL and
TACC1 were identified as modulators of the metastasis suppressive effect of
MBNL1 in breast cancer.
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CHAPTER 1: INTRODUCTION
1. Breast cancer incidence, classification and clinical outcomes
Breast cancer is a common disease. Worldwide, there were an estimated
1,671,000 new cases diagnosed and 522,000 deaths from breast cancer in 2012
(Ferlay et al. 2012). In the United States, breast cancer is the most commonly
diagnosed cancer. There will be an estimated 231,840 new breast cancer cases
diagnosed and an estimated 40,290 deaths from breast cancer in 2015 (Table
1.1). The lifetime risk of being diagnosed with breast cancer for a woman in the
US is 12.3% (Howlader et al. 2015).
Table 1.1 Incidence of common cancers in the United States for 2015

Clinically, breast cancer can be classified by stage, grade, hormone
receptor/HER2 status, and gene expression signature. Stage is defined by the
size of the primary tumor and the degree to which it has spread to other sites in
the body. The most commonly used staging system is called TNM (Tumor,
regional lymph Node, Metastasis). This system assesses primary tumor size,
degree of regional lymph node involvement and presence of cancer metastasis to
distant organs in order to determine the cancer stage. Stages range from I to IV.
Stage I breast cancers are small, have not detectably spread to regional lymph
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nodes and have not metastasized, and stage IV cancers are those that have
metastasized to distant organs. Stages II and III have intermediate levels of
cancer size and spread (Sobin et al. 2010). Grade refers to the appearance of
the primary tumor tissue and assesses how similar to normal breast tissue the
tumor tissue appears. In the commonly used Nottingham grading system, each of
the following factors contributes to the final assigned tumor grade: 1) The percent
of the tumor tissue retaining normal milk duct structures. 2) The size and shape
of the nucleus in the cancer cells. 3) The number of actively dividing cells.
Hormone receptor/HER2 status refers to the expression of the estrogen receptor
(ER), progesterone receptor (PR) and of the erb-b2 receptor tyrosine kinase 2
(ERBB2, also known as HER2/neu) by breast cancer cells. The expression of
ER, PR and HER2 is typically assessed by immunohistochemistry, and the
cancer is then designated as being positive or negative for expression of each of
these factors. The expression of these factors are important for deciding the
treatment of a breast cancer, as the effectiveness of drugs commonly used to
treat breast cancer is largely determined by cancer cell ER, PR and HER2
expression. Breast cancers can also be categorized by their gene expression
signature, also known as their intrinsic molecular subtype. Transcriptomic
profiling of large sets of breast cancers has shown that breast cancers can also
be divided into groups based on gene expression signatures (Bertucci et al.
2000; Perou et al. 2000; Sorlie et al. 2001; Sorlie et al. 2003). The molecular
subtypes of breast cancer based on gene expression profiling have been
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identified as luminal A, luminal B, HER2-enriched, basal-like, normal-like and
claudin-low, the last two of which are rare. The luminal and basal subgroups are
so named because their patterns of gene expression are similar to that of normal
breast luminal and basal tissues. Classification of breast cancers by gene
expression subtype, in addition to classification by stage, grade and
receptor/HER2 status, can add information that is useful for prognosis and
treatment (Kittaneh et al. 2013). Each of these criteria for classifying breast
cancer is correlated with survival outcomes, but the stage and receptor status are
currently the primary determinants of which therapies are used for treatment.
However, gene expression signature information is increasingly being used to
develop and test new targeted therapies (Eroles et al. 2012).
Depending on how it is classified using the systems described above, a
breast cancer may be treated with surgery, radiation and non-specific cytotoxic
chemotherapies or anti-angiogenic therapies. However, a primary consideration
for breast cancer treatment is the receptor status of the cancer, as cancers that
are ER/PR positive, and/or HER2 positive are treated differently from triple
negative/basal-like cancers. This is because specific targeted therapies exist for
hormone receptor positive and HER2 positive breast cancers, and these
treatments confer a survival advantage over treatment with non-specific
therapies. There is a lack of targeted therapies for triple negative/basal-like
breast cancers, as these cancers do not express the factors that are targeted by
these specific drugs. The established treatment for hormone receptor positive

3

breast cancers is administration of drugs aimed at reducing estrogen signaling,
thereby reducing tumor growth. These drugs include tamoxifen, a small molecule
that binds to ER and inhibits estrogen signaling in breast tissue. In postmenopausal women, aromatase inhibitors, including the small molecules
anastrozole, exemestane and letrozole, are used to inhibit the actions of
aromatase. The enzymatic activity of aromatase converts androgens into
estrogen, and anti-aromatase therapy reduces systemic estrogen levels (Miller et
al. 2014). Additionally, in pre-menopausal women, drugs can be used to
suppress ovarian estrogen production in order to reduce systemic estrogen
levels, although the effectiveness of this therapy in addition to tamoxifen therapy
is not dramatic (Francis et al. 2015). The established therapy for HER2 positive
breast cancers is trastuzaumab (Herceptin), an antibody directed against the
extracellular domain of HER2. Trastuzaumab is effective in improving the survival
of patients with HER2 expressing breast cancers (Piccart-Gebhart et al. 2005;
Smith et al. 2007). However, breast cancers that have metastasized to distant
organs remain difficult to treat, and women with breast cancer that has not
spread from the primary site, or has spread regionally have a much higher 5-year
survival rate compared to those who have cancer that has spread to distant
organs (Figure 1.1A). Therefore, the majority of deaths from breast cancer are
due to metastatic disease.
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Figure 1.1 Breast cancer survival and metastatic progression
(A) The 5-year survival rate of breast cancer patients in the United States,
divided by level of spread of the cancer. (B) Illustration depicting the metastatic
cascade.

2. Cancer metastasis
From the above data, it is clear that the survival rate of breast cancer
patients is dependent on the extent of cancer progression (Figure 1.1A). Because
of this, it is important to understand the mechanisms by which cancer cells can
successfully spread through the body and colonize distant organs, a process
called metastasis. In this process, a cancer cell from the primary tumor moves
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away from the primary tumor and into the surrounding tissue, intravasates into
blood vessels, survives in circulation, extravasates out of blood vessels, and
successfully survives and proliferates in a secondary organ (Chiang and
Massague 2008) (Figure 1.1B). It is unlikely that a cancer cell from the primary
tumor has the capacity to carry out all of these steps. Indeed, very few cancer
cells from a primary tumor make it through all of the steps of the metastatic
process. In animal models of metastasis, less than 0.01% of cancer cells in
circulation result in macroscopic metastases (Chambers et al. 2002; Luzzi et al.
1998). In addition to the qualities intrinsic to the cancer cell, both the
microenvironment of the primary tumor and the microenvironment of the distal
organ to which the cancer has metastasized play roles in modulating the
likelihood of metastasis (Joyce and Pollard 2009). Therefore, because of the
complex nature and clinical importance of metastasis, it is of great interest to
identify molecules that contribute to this process.
The first step of metastasis is cancer cell movement into blood vessels, a
process called intravasation. Cancer cells may intravasate into vessels that are in
direct contact with the tumor, or the cancer cell may first invade into the
surrounding tissue and then intravasate into blood vessels. Cancer cell invasion
can be promoted by local environmental stresses such as hypoxia, pH level and
nutrient deprivation as well as the presence of various stromal cell types and the
composition of the extracellular matrix (Chang and Erler 2014; Quail and Joyce
2013). Cancer cells invade by moving through the extracellular matrix and normal
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tissue that surrounds the primary tumor. These cancer cells can then intravasate
into systemic circulation by moving through the layers of endothelial cells that
comprise the blood vessel walls. Normally, endothelial cells act as a barrier to the
movement of cells in to or out of the bloodstream, and therefore cancer cell
movement across the endothelial cell layer is an aberrant occurrence. Cancer
cells may intravasate through active and passive mechanisms. Tumor
vasculature is abnormal, with leaky endothelial cell junctions and abnormal
coverage by pericytes, features that allow for easier cancer cell intravasation
(Dudley 2012; Xian et al. 2006). Cancer cells may also actively intravasate into
vessels through either paracellular (movement through the junctions between
endothelial cells), or transcellular (movement directly through the body of an
endothelial cell) mechanisms. Many molecules that enhance invasion generally
also enhance intravasation. Molecules expressed by breast cancer cells that are
important for paracellular intravasation include N-WASP, which reorganizes the
actin cytoskeleton by promoting invadopodia formation, and also enhances
invasion and intravasation (Gligorijevic et al. 2012). Increased cancer cell
expression of the matrix metalloproteinase MT4-MMP disrupts blood vessel
integrity in the tumor environment, which allows for increased cancer cell
intravasation (Chabottaux et al. 2009). Another metalloproteinase, ADAM12, is
expressed in breast cancer tumor vasculature but not in the vasculature of
normal breast tissue. The ectodomain shedding of endothelial cell vascular
endothelial cadherin and of the angiopoietin 1 receptor TIE2 is mediated by
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ADAM12, and could play a role in promoting cancer cell intravasation by
disrupting endothelial cell junctions (Frohlich et al. 2013). Microenvirnomental
factors can also affect intravasation: macrophages can enhance breast cancer
cell intravasation by inducing cancer cell expression of Mena (an epidermal
growth factor-responsive cell migration protein) through colony-stimulating factor1 receptor signaling (Keirsse et al. 2014). Transcellular intravasation is another
method breast cancer cells can use to move into vessels, and a role for
endothelial cell myosin light chain kinase has been demonstrated in this process
(Khuon et al. 2010). Once successfully intravasated, cancer cells in circulation
encounter and must survive multiple stresses, including the mechanical shear
stress of the bloodstream, detachment from the ECM, and destruction by immune
cells.
Cancer cells then move out of circulation in a process called
extravasation. During extravasation, cancer cell must again traverse the
endothelial layer of blood vessels. The first step of extravasation is the adhesion
of cancer cells to the endothelial cells of a blood vessel. This adhesion can occur
after cancer cell arrest in capillaries due to size constraints, but can also involve
cancer cell rolling on the vessel wall before firm adhesion (Geng et al. 2012;
Kienast et al. 2010; Stoletov et al. 2010). Adhesion involves a large number of
factors on both the cancer and endothelial cells. Initial attachment can occur
through the interactions of cancer cell expressed N-cadherin, Sialyl Lewis A
and/or CD44 with endothelial cell expressed N-cadherin and/or E-selectin.
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Stabilization of cancer cell-endothelial cell interaction further depends on
integrins, CD44 and/or Mucin 1 (Reymond et al. 2013). The cancer cell then
migrates through the endothelial cell layer and into the surrounding tissue. Once
the cancer cell has extravasated and is located in a distant organ, the
environment of that organ and the intrinsic programing of the cancer cell both
contribute to the suppression or promotion of cancer cell survival, proliferation,
and ultimately formation of metastatic nodules in that distal organ.
3. Post-transcriptional regulation of gene expression
For metastasis to occur, cancer cells must acquire cellular phenotypes
that enable their migration into distant organs, where their subsequent survival
and proliferation lead to end-organ failure. The enhanced invasiveness and
migratory capacity necessary for metastasis can be generated through the
coordinated expression of specific gene sets. Post-transcriptional regulation of
gene expression is a method of doing this, and refers to processes that affect the
expression of a messenger RNA (mRNA) after transcription. The posttranscriptional control of mRNA expression is determined by interactions between
regulatory cis-elements and trans-factors. Therefore, regulated modifications to
cis-elements and interacting trans-factors determine the identity, localization and
expression of a transcript. These processes include alternative splicing,
alternative polyadenylation site selection, RNA editing, post-transcriptional
nucleotide modification, and non-templated polyadenylation of the 3’ end of a
mRNA (Li and Mason 2014; Liu et al. 2014; Norbury 2013). Alterations to
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regulatory trans-factors can also affect post-transcriptional gene expression. The
major types of trans-factors are RNA binding proteins and microRNAs, both of
which carry out their regulatory roles through direct interactions with transcripts.
Importantly, a single trans-factor can interact with and regulate the expression of
multiple transcripts, thereby coordinating the expression of gene sets.
Pre-mRNA alternative splicing and alternative polyadenylation site
selection
Pre-mRNA alternative splicing is a major method of transcriptome
diversification. Although there are approximately 20,000 genes in the human
genome, analysis of high-throughput RNA sequencing data has revealed that
from 95-100% of human genes express alternatively spliced transcript variants
(Pan et al. 2008; Wang et al. 2008). Interestingly, the amount of alternatively
spliced transcripts increases with increasing organism complexity, and therefore
the prevalence of alternative splicing in humans is thought to be necessary for
diversifying the human proteome (Nilsen and Graveley 2010). Pre-mRNA
alternative splicing is the process by which specific exons and introns are actively
included or excluded from a transcript. Four major types of alternative splicing
exist: exon inclusion, exon exclusion, mutual exon exclusion, and intron retention.
Alternative splicing adds a regulatory layer to the basal splicing of all introncontaining transcripts. The basic mechanism of splicing, where introns are
removed and exons are joined together, is controlled by cis-elements in the premRNA. The conserved elements that are recognized by the spliceosome are
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exon-intron junctions at the 5’ and 3’ ends of introns, the branch point sequence,
located upstream of the 3’ splice site, and the polypyrimidine tract, which is
located between the branch point sequence and the 3’ splice site. The 5’ splice
site has a conserved GU dinucleotide and the 3’ splice site has a conserved AG
dinucleotide. These elements are then bound in a defined order by the small
nuclear ribonucleoprotein particles (snRNPs) U1, U2, U4/U6, and U5, which are
central components of the spliceosome. The spliceosome is a large RNA-protein
complex that catalyzes the removal of introns and joining of exons (Lee and Rio
2015). In eukaryotes, exon definition is the major mechanism used by the basal
splicing machinery.
Alternative splicing is directed by cis-regulatory sequence elements and
trans-factors. These regulatory elements are divided into four types: exonic
splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing
enhancers (ISEs), and intronic splicing silencers (ISSs). The best-studied classes
of proteins that bind to these regulatory elements and influence exon choice are
the ubiquitously expressed members of the heterogeneous nuclear
ribonucleoprotein (hnRNP) family (Huelga et al. 2012), and proteins in the serinearginine rich (SR) protein family (Anko 2014). Another class of proteins that play
roles in regulating alternative splicing are those that exhibit tissue-specific
expression patterns and are involved in tissue differentiation. These include
proteins from the NOVA (neuro-oncological ventral antigen)(Ule et al 2003;
Zhang et al. 2010), RBFOX (Fox RNA-binding)(Weyn-Vanhentenryck et al. 2014;
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Yeo et al. 2009; Zhang et al. 2008), CELF (CUG binding, Elav-like), and MBNL
(Muscleblind-like) (Kalsotra et al. 2008; Ladd et al. 2001; Wang et al. 2012,
Wang et al. 2015) families. These proteins control alternative splicing by binding
in the upstream intron, downstream intron or in the regulated exon itself to control
exon inclusion or skipping. Some of these factors act to recruit spliceosome
machinery, while others act to block the actions of the spliceosome. These
regulatory factors have also been shown to antagonize each other’s functions
(Zhu et al. 2001). It is thought that the developmental stage and tissue-specific
expression patterns of these factors dictate their activity.
Although deadenylation and decapping accounts for bulk mRNA turnover,
cis-elements and trans-factors allow for the modulation of transcript stability. Ciselements that regulate mRNA decay are commonly found in 3’UTRs. Many such
elements have been identified, and are usually defined by sequence. However,
cis-elements defined by structure rather than sequence have been identified as
modulators of mRNA decay (Goodarzi et al. 2012). Both sequence-specific and
structural elements interact with trans-factors, which then can affect the stability
of the transcript through recruitment or inhibition of mRNA decay machinery.
In addition to alternative splicing, pre-mRNAs are subject to alternative
cleavage and polyadenylation (APA). APA produces transcripts with different 3’
ends, which can affect post-transcriptional gene regulation. APA is a prevalent
mode of regulation, as approximately 70% of human transcripts have alternative
poly(A) containing products as assessed by RNA sequencing methods (Derti et
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al. 2012). The location of many regulatory elements, 3’UTRs are enriched in sites
recognized and bound by trans-factors. These interactions can control the
expression of that transcript. Therefore, shortening of a 3’UTR through APA can
allow escape from regulation by specific trans-factors. This type of dysregulation
has been observed in cancers (Mayr and Bartel 2009). In a subset of breast
cancers, among transcripts with significantly different 3’UTR lengths, shorter
3’UTRs were associated with shorter overall patient survival (Lembo et al. 2012).
The control of the length of the poly(A) tail is another important method the
cell uses to regulate stability and maintain steady-state levels of transcripts.
Normally, poly(A) tails of 100-250 nucleotides are added to the 3’ end of each
mRNA by the actions of poly(A) polymerase (PARP) and nuclear poly(A) binding
protein (PABPN1). The presence of a poly(A) tail allows a transcript to be
exported to the cytoplasm and engage with the translation machinery. Once in
the cytoplasm, the length of a transcript’s poly(A) tail is then controlled by the
opposing actions of deadenylases and adenylases. Generally, the PAN2/3
complex (poly(A) nuclease 2/3) is the initial factor that trims the poly(A) tail of an
mRNA, and its activity is stimulated by PABP (poly(A) binding protein). Further
deadenylation is carried out by the CCR4-NOT complex, which can be inhibited
or stimulated by the binding of transcript-specific RBPs. Once a transcript has
been deadenylated to a certain point, RNA degradation occurs (Norbury 2013).
Molecular mechanisms of mRNA degradation
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In eukaryotic cells, a combination of factors dictate the stability of
messenger RNAs (mRNAs). Ribonucleases control mRNA degradation through
defined pathways and trans-acting factors and cis-acting elements control the
rate of mRNA decay. Two critical cis-acting determinants of mRNA stability are
incorporated co-transcriptionally: the 7-methyl-guanosine cap (m7G) which is
added to the 5’ end of the transcript, and the poly(A) tail which is added to the 3’
end of the transcript. These two additions protect the transcript from immediate
destruction by exonucleases, and their removal is crucial to normal turnover of
mRNAs (Yamashita et al. 2005). Transcripts are constantly subjected to the
actions of ribonucleases so as to maintain steady-state levels of mRNA in the
cell. Transcripts can be further subject to regulated decay, both by cis-elements
in their sequence and in response to various stimuli that regulate the level of
trans-acting factors such as RBPs and miRNAs.
Messenger RNAs are degraded by the enzymatic actions of
ribonucleases, and these RNA degradation enzymes carry out their actions in a
specific order. Here, a general overview of the major factors in these pathways in
eukaryotic cells is given. The primary pathway of mRNA decay is the
deadenylation-dependent pathway. In this pathway, the first step of mRNA
degradation is removal of the poly(A) tail. This requires the action of
deadenylases, which are 3’-5’ exoribonucleases with a high preference for a
poly(A) substrate. Deadenylases and poly(A) polymerases dynamically control
poly(A) tail length in the cytoplasm, and poly(A) tail length is a major determinant
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of mRNA stability. Generally, the poly(A) tail of a transcript is bound by PABP
(poly(A) binding protein) in the cytoplasm, and PABP interacts with eIF4G, a
component of the eIF4F complex which binds the m7G cap at the 5’ end of the
transcript. This interaction promotes the recruitment of the translation initiation
complex as well as protects the transcript from degradation. Once deadenylases
have shortened the poly(A) tail below a threshold length, PABP no longer
interacts with the tail and the transcript is left unprotected from further actions of
ribonucleases (Kim et al. 2006; Tharun and Parker 2001; Wilusz et al. 2001). The
major deadenylase containing complexes that are active in metazoans are
CCR4-CAF1-NOT, PAN2-PAN3 and PARN (Yan 2014). After removal of the
poly(A) tail by the actions of a deadenylase complex, the remaining RNA can be
degraded in either a 3’-5’ or 5’-3’ direction. 3’-5’ degradation occurs through the
action of the exosome, a large multi-subunit complex with exonuclease activity
(Houseley and Tollervey 2009). The m7G cap is then removed by DcpS
(scavenger decapping enzyme). Messenger RNA can also be degraded in the 5’3’ direction after deadenylation. The first step in this process is removal of the
m7G cap by the decapping complex, which requires the enzymatic action of
DCP2 (van Dijk et al. 2002; Wang et al. 2002). The decapping complex also
contains proteins that enhance decapping. In metazoans, these cofactors are
DCP1, EDC3, EDC4, PAT1B, DDX6, and the LSM1-7 complex. These factors are
not all required for decapping of all mRNAs, but can act in a transcript specific
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manner (Arribas-Layton et al. 2013; Fenger-Gron et al. 2005, Ling et al. 2011).
After decapping, the remaining RNA is degraded 5’-3’ by the exonuclease XRN1.
Messenger RNA may also be degraded in a deadenylation-independent
manner. However, this pathway is thought to play a very minor role in bulk mRNA
decay in eukaryotic cells. The existence of this pathway in yeast has been
demonstrated by studying the regulated decay of the RPS28B transcript.
Initiation of this pathway requires the recruitment of the decapping complex
component EDC3 to the transcript, which in turn recruits the decapping enzyme
DCP2. After removal of the m7G cap, the RNA is degraded 5’-3’ by XRN1 (Badis
et al. 2004).
An additional type of mRNA decay utilizes endoribonucleases. This
method of mRNA degradation differs from the pathways described above
because removal of the poly(A) tail or the 5’ cap is not necessary for initiation of
decay. Instead, endonucleases act on a capped, polyadenylated mRNA and
cleave it. The resulting RNA pieces are then destroyed by the actions of the
exoribonucleases XRN1 and the exosome. Instances of endoribonucleasemediated mRNA decay in metazoans have been reported, but have not been
heavily studied. Generally, these endonucleases have highly specific transcript
targets, their action is activated by external stimuli, their actions can be localized,
and they cleave at specific sequences. This is in contrast to the deadenylation
and decapping that facilitates constitutive bulk mRNA turnover. The best studied
of these endonucleases is PMR1, which was discovered in Xenopus extracts as
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the endonuclease responsible for deadenylation independent decay of the
albumin transcript in response to estrogen (Yang and Schoenberg 2004). In
human cells, the PMR1 endonuclease is associated with polysomes, and
localization of PMR1 to the leading edge of MCF7 breast cancer cells enhances
cell motility in a scratch assay (Gu et al. 2012). Other proteins that have
demonstrated endonuclease activity on specific mRNA substrates in metazoans
are IRE1/ERN1 (endoplasmic reticulum to nucleus signaling 1), ZC3H12A (zinc
finger CCCH-type containing 12A), SMG6 (SMG6 nonsense mediated mRNA
decay factor), and APE1 (apurinic/apyrimidinic DNA endonuclease
1)(Schoenberg 2011). SMG6 acts in the nonsense mediated decay pathway
(Eberle et al. 2009), and therefore typically acts as a quality control factor rather
than a regulator of the decay of specific mRNAs in response to stimulus.
mRNA stability regulatory pathways
Transcripts that do not contain open reading frames (ORFs) are subject to
active degradation by the cell to ensure the production of functional proteins. The
recognition of transcripts without ORFs occurs through multiple mechanisms,
depending on the problem with the transcript. Together, these are referred to as
surveillance pathways. These are 1) nonsense mediated decay (NMD), which
occurs when an mRNA has a premature termination codon (Kervestin and
Jacobson 2012). 2) nonstop mediated decay (NSD), which happens when an
mRNA does not contain an in-frame termination codon (Frischmeyer et al. 2002),
and 3) No-go decay (NGD), which takes place when ribosomes stall at the 5’ end
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of an mRNA (Doma and Parker 2006). These pathways of decay are triggered by
problems in the processing or sequence of the transcript. Interestingly, NMD can
also participate in the regulated decay of transcripts in a process called
alternative splicing coupled NMD (AS-NMD). AS-NMD acts through selective
degradation of mis-spliced mRNAs. Types of alternative splicing that trigger NMD
are retention of a premature termination codon-containing exon or intron, splicing
that leads to an elongated 3’UTR, and splicing that results in the presence of an
upstream open-reading frame (Sibley et al. 2014). Alternative splicing can also
lead to intron retention. In addition to triggering NMD in the cytoplasm, this can
lead to a block on the export of a transcript to the cytoplasm, and thereby induce
transcript degradation by the nuclear exosome (Ge and Porse 2013).
Cytoplasmic RNA granules and mRNA stability
The subcellular localization of a transcript also contributes to its stability.
Processing bodies (P-bodies) and stress granules are two major types of
cytoplasmic RNA granules that are sites of regulated mRNA decay and storage.
Stress granules form in response to various stresses. These stress stimuli
include oxidative stress, hypoxia, amino acid starvation, endoplasmic reticulum
stress, heat shock, UV irradiation and viral infection. These different stimuli each
induce the activity of specific kinases that then phosphorylate eIF2-alpha
(eukaryotic initiation factor 2) (Kedersha et al. 1999). This phosphorylation event
halts translation initiation, but does not affect actively elongating ribosomes.
Stress granules contain translation initiation factors, 40S ribosomal subunits and
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mRNAs bound to the translation pre-initiation machinery. A large number of other
RBPs have also been found in stress granules, and the specific composition of a
given stress granule is dependent on the identity of the cell and the type of
stress. Another characteristic of mRNAs in stress granules is that they retain their
poly(A) tails and remain in a closed loop formation with the cap complex
(Anderson and Kedersha 2008). Components of stress granules disperse once
the stress is removed, and translation of the mRNAs can resume. Stress granule
formation may play a role in cancer progression. In a mouse xenograft model of
osteosarcoma metastasis to the lung, depletion of the stress granule nucleating
factor G3BP1 reduced both number of stress granules per cancer cell and
reduced the number of metastatic nodules in the lung (Somasekharan et al.
2015). Although this is a correlative finding, it is consistent with stress granule
formation promoting metastasis.
A second major type of cytoplasmic RNA granule is processing bodies,
which have distinct components from stress granules. However, P-bodies and
stress granules also have many overlapping components and functions, and
these protein components, as well as RNA transcripts, can move dynamically
between the two granule types (Kedersha et al. 2005). P-body components
include mRNA degradation, mRNA surveillance and miRNA-mediated gene
silencing factors. The decapping enzyme DCP2 is a characteristic component of
these foci. Unlike stress granules, P-bodies are constitutively present. Although
they contain mRNA decay machinery, and are thought to be the sites of mRNA
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decay, the presence of P-bodies is not required for global or specialized RNA
decay to occur (Eulalio et al. 2007; Stoecklin et al. 2006).
4. RNA binding proteins, tumorigenesis and cancer progression
RNA interacting proteins are abundant, with ~550 mRNA-interacting
proteins common to both HeLa and HEK293 cells (Baltz et al. 2012; Castello et
al. 2012). Through their interactions with RNA, these proteins mediate a variety
of regulatory processes that have wide-ranging downstream effects in
development, homeostasis and pathological processes. The majority of RNA
binding proteins bind multiple RNA transcripts and/or other RNA molecules and
in doing so can impact the regulation of those RNAs. Given their ability to
coordinately regulate sets of transcripts, proteins belonging to this group have the
potential to confer attributes that affect the metastatic potential of cancer cells.
Indeed, recent studies have noted such effects on breast cancer progression for
a variety of RNA-binding proteins. The metastasis modulating effects of these
RNA-binding proteins have been shown to be generated through different posttranscriptional regulatory steps, including direct modulation of transcript stability
by TARBP2 (Goodarzi et al. 2014) and RBM47 (Vanharanta et al. 2014), as well
as regulation of alternative splicing patterns by HNRNPM (Xu et al. 2014). The
role of RNA binding proteins in breast cancer tumorigenesis, in contrast to cancer
progression, has been more heavily studied. Among the best-studied RBPs in
breast tumorigenesis are ELAVL1 (embryonic lethal abnormal vision-like 1, also
known as HuR) and ZFP36 (zinc finger protein 36, also known as TTP). Both are
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AU rich element (ARE) -binding proteins, and ELAVL1 is commonly upregulated
in breast cancer, while ZFP36 is commonly downregulated (Sanduja et al. 2010;
Abdelmohsen and Gorospe 2010).
5. Muscleblind-like family: Identification and structure
One RNA binding protein that has been implicated in human genetic
disease and in the regulation of alternative splicing is Muscleblind-like 1
(MBNL1). The Muscleblind-like family of proteins is present in organisms ranging
from worms to humans. Muscleblind-like proteins do not exist in bacteria, fungi or
plants, and only occur in metazoans. Invertebrates have one muscleblind-like
gene, while the majority of vertebrates have three muscleblind-like genes
(Pascual et al. 2006). Members of this family contain highly conserved cysteinecysteine-cysteine-histidine (CCCH) zinc finger domains with which they bind
RNA. These CCCH zinc finger domains are common, and are found in over 1000
proteins. CCCH zinc finger domains bind specific sequence motifs in RNA.
Consistent with this observation, SELEX studies have determined that MBNL1
binds the RNA motif YGCY (Goers et al. 2010), while CLIP-seq studies have
identified an enrichment of UGC and GCU containing 4mers in MBNL1-bound
sites in mouse myoblasts (Wang et al. 2012). Crystal structures of the MBNL1
CCCH zinc finger domains, both while bound to RNA with the sequence
CGCUGU, and while not bound to RNA, have been solved (Teplova and Patel
2008). These structures show that the two pairs of zinc fingers have a symmetric
fold where the two zinc fingers in each pair are connected by a linker that orients
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their RNA binding surfaces away from each other, making the RNA fold into an
antiparallel form. This structure as well as other in vitro biochemical binding data
(Goers et al. 2010) suggests a model where the zinc fingers of MBNL1 interact
with the 5’-GC steps in RNA that folds into hairpin structures with bulged and
unpaired uridines.
MBNL proteins in development
Work on a Drosophila melanogaster mutant led to the first characterization
of a muscleblind family member, with the observation that in Drosophila,
muscleblind is required for normal development of photoreceptor cells as well as
for normal muscle differentiation and attachment (Begemann et al. 1997; Artero
et al. 1998). In mammals, the three members of the Muscleblind-like family are
MBNL1, MBNL2 and MBNL3, and all contain four tandem CCCH zinc finger
domains. These highly similar proteins exhibit tissue-specific expression
patterns. MBNL1 is the most highly expressed member of the family, and is
detected in adult skeletal muscle, heart, brain, intestine, kidney, liver, lung and
placenta. Mice with genetic knockout of MBNL1 develop muscle weakness,
cataracts and cardiac pathology (Dixon et al. 2015; Kanadia et al. 2003). Loss of
MBNL1 function results in a shift to fetal and embryonic stem cell-like transcript
splicing patterns, and also impairs erythroid terminal differentiation (Cheng et al.
2014; Han et al. 2013; Lin et al. 2006). MBNL2, like MBNL1, is detectable in most
adult tissues, with the highest expression in brain, and has decreased expression
in heart and skeletal muscle compared to MBNL1. Mice null for MBNL2 do not
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display abnormal muscle development, but they exhibit sleep disturbances,
impaired learning and are prone to seizures (Charizanis et al. 2012). Of the three
MBNL members, MBNL3 has the lowest expression levels. MBNL3 is primarily
expressed during embryonic development, but is also detectable in adult lung,
spleen and testis. Interestingly MBNL3 expression is decreased in myoblasts
when they are induced to differentiate, and overexpression of MBNL3
suppresses myoblast differentiation (Kanadia et al. 2003; Lee et al. 2007;
Squillace et al. 2002). These expression patterns and developmental phenotypes
are consistent with a model where MBNL1 and MBNL2 promote normal tissue
differentiation while MBNL3 acts as a suppressor of differentiation. Together,
these MBNL1-dependent developmental phenotypes and the lack of MBNL
orthologs in single cell organisms suggest that MBNL family proteins function
primarily to ensure correct differentiation of tissues.
MBNL molecular mechanisms
MBNL1 has a well-characterized role in the regulation of pre-mRNA
splicing. The first pre-mRNAs found to have MBNL1-dependent alternative
splicing were identified because these transcripts had been found to have altered
splice forms in myotonic dystrophy, a disease in which MBNL1 has a pathogenic
role, as discussed in the next section. These first identified alternatively spliced
genes were TNNT2 (cardiac troponin T type 2) and INSR (insulin receptor) (Ho et
al. 2004). In a study examining the mechanism of MBNL1-regulated alternative
splicing of the TNNT2 pre-mRNA, MBNL1 was found to bind to a stem-loop

23

structure in the polypyrimidine tract of the intron upstream of the alternative exon
in TNNT2 pre-mRNA. MBNL1 binding was found to inhibit the formation of the
spliceosome complex by modulating the local RNA structure, which then
interfered with U2AF2 binding and led to exon skipping (Warf et al. 2009). More
recently, genome-wide sequencing and computational analyses have found
many more MBNL family protein dependent splicing events (Charizanis et al.
2012; Du et al. 2010; Wang et al. 2012). Mechanistically, MBNL protein splicing
function is dependent on where the protein binds relative to the alternative exon.
MBNL1 and MBNL2 binding on the alternative exon or within the upstream intron
usually leads to skipping of the alternative exon (Charizanis et al. 2012; Du et al.
2010; Wang et al. 2012). MBNL1 binding to the downstream intron promotes
retention of the alternative exon. In addition to the cis-acting sequences in a
transcript, trans-acting factors can also influence the binding of MBNL1 to RNA.
A study has shown that the DEAD-box RNA helicase DDX5 promotes MBNL1
binding to the stem-loop regulatory element in the TNNT2 pre-mRNA (Laurent et
al. 2012). Interestingly, another DEAD-box helicase, DDX6, has been found to
interact with and unwind CUG repeat expansion RNA hairpins, leading to a
decrease of MBNL1 binding to these RNA structures (Pettersson et al. 2014).
MBNL1 co-immunoprecipitates with several proteins in human myoblasts,
including hnRNP H,H2, H3, F, A2/B1, K, L, DDX5, DDX17 and DHX9, and these
may act in concert with MBNL1 to affect RNA splicing (Paul et al. 2011). More
definitively, CLIP-seq analysis of MBNL and CELF1 determined that these
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proteins have opposing effects on the splicing of a large set of alternative exons
(Wang et al. 2015).
MBNL1 has also been found to developmentally regulate alternative
poly(A) site selection in mouse embryonic fibroblasts through directly binding to
3’UTRs (Batra et al. 2014). CLIP-seq analysis of MBNL1 and MBNL2 in mouse
myoblasts in combination with cellular fractionation and transcriptomic profiling
led to a proposed model wherein MBNL1 binding to 3’UTRs promotes localization
and cytoskeletal trafficking of transcripts, which then promotes secretion of their
protein products (Wang et al. 2012). Another study analyzed CLIP-seq of MBNL1
in mouse myoblasts and proposed that MBNL1 binding destabilizes transcripts
(Masuda et al. 2012). Clearly, MBNL1 has multiple mechanisms through which it
post-transcriptionally regulates gene expression.
6. MBNL and human genetic diseases
Myotonic dystrophy
To date, most studies on MBNL family proteins have investigated the
mechanism through which they contribute to the pathology of myotonic
dystrophy, a human genetic disease. Myotonic dystrophy is the most common
muscular dystrophy that affects adults, with an estimated global incidence of 1
case per 8,000 people. People affected with this disease exhibit muscle
weakness and atrophy, cardiac conduction defects, cataracts, diabetes, male
frontal balding, various behavioral changes and hypersomnia (Udd and Krahe
2012). Two forms of the disease exist, myotonic dystrophy type 1 (MD1) and
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myotonic dystrophy type 2 (MD2), which are classified according to the genic
location of the causative mutation. In both types, the causative mutation is a
nucleotide repeat expansion in a non-coding region of a gene. In type 1, this is a
(CTG)n repeat expansion in the 3’UTR of the DMPK (Dystrophia Myotonica
Protein Kinase) gene (Aslanidis et al. 1992; Brook et al. 1992; Harley et al. 1992;
Mahadevan et al. 1992). In type 2 disease this is a (CCTG)n repeat expansion in
the first intron of the CNBP (CCHC-type zinc finger, Nucleic acid Binding Protein)
gene (Liquori et al. 2001).
The mechanism through which these repeat expansions lead to the
pathology associated with the disease has been intensely studied. The prevailing
model for how these repeat expansions cause the pathologic features of
myotonic dystrophy is an RNA gain-of-function mechanism (Figure 1.2A). In this
model, transcripts containing these repeat expansions accumulate in the nucleus,
where they bind proteins, effectively sequestering these proteins and preventing
their normal actions in the cell. Several lines of evidence point to this RNA gainof-function model being a major contributor to myotonic dystrophy pathogenesis.
Mice null for DMPK exhibit late onset myopathy, but do not display myotonia and
cataracts, two phenotypes characteristic of myotonic dystrophy (Reddy et al.
1996). Also, although SIX5 (Sine oculis-related homeo box 5), the gene located
immediately downstream of DMPK, has reduced expression levels in MD1 due to
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Figure 1.2. RNA gain-of-function model for myotonic dystrophy 1 pathogenesis
Illustration depicting the toxic gain-of function RNA model for the pathogenesis of
myotonic dystrophy 1. An expansion of the number of CTG trinucleotide repeats
in the 3’UTR of the DMPK gene, which normally contains 5-37 CTG repeats,
leads to the accumulation of DMPK transcripts with CUG trinucleotide repeat
expansions. This RNA then has a gain-of-function by binding and sequestering
MBNL1, preventing the normal functions of MBNL1 in the cell.

the expanded (CTG)n repeat in the 3’UTR of DMPK (Klesert et al. 1997), mice
null or heterozygous for SIX5 develop cataracts but no abnormal muscle
phenotype (Klesert et al. 2000; Sarkar et al. 2000), again, suggesting that SIX5
levels are not sufficient to phenocopy the symptoms of myotonic dystrophy. The
evidence in favor of the RNA gain-of-function model includes a characteristic
accumulation of nuclear foci in muscle samples from individuals affected with
myotonic dystrophy, and that these nuclear foci contain the expanded repeat
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transcripts (Liquori et al. 2001; Mankodi et al. 2001; Taneja et al. 1995). The
identification of MBNL proteins as (CUG)n repeat binding proteins (Miller et al.
2000) and the discovery that MBNL proteins colocalize with the (CUG)n
expanded repeat-containing RNA in nuclear foci further supports this model
(Fardaei et al. 2001; Mankodi et al. 2001). Another critical finding in support of
this model was that MBNL1 null mice recapitulate many of the phenotypes
characteristic of myotonic dystrophy, including myotonia and cataract
development (Kanadia et al. 2003).
It is thought that the pathogenesis of myotonic dystrophy is caused by the
dysregulation of the alternative splicing of a set of transcripts normally regulated
by MBNL proteins. In favor of this spliceopathy model, a study compared global
splice forms in MBNL1 null mice with those in a mouse model of MD1, where
animals were engineered to express a transgene consisting of 250 CUG repeats
in the human skeletal muscle actin gene 3’UTR (Mankodi et al. 2000). This
showed a ~80% overlap in splice forms in the two mice (Du et al. 2010). Taken
together, the evidence supports a model for myotonic dystrophy pathogenesis
where expanded repeats in non-coding genic regions result in the accumulation
of “toxic” repeat-containing RNAs that bind MBNL proteins and prevent them
from carrying out their usual functions.
Spinocerebellar ataxia 8
Although their role in myotonic dystrophy is the most heavily studied, there
is evidence that MBNL1 functions in the pathogenesis of another human genetic
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disease, spinocerebellar ataxia 8 (SCA8). SCA8 is a slowly progressing
neurodegenerative disease that affects the cerebellum. The causative SCA8
mutation is a CAG CTG repeat expansion in the overlapping genes ATXN8OS
and ATXN8, which are located on opposite DNA strands (Koob et al. 1999). This
expansion results in an expanded run of glutamines in the protein product of
ATXN8, and a CUG trinucleotide repeat expansion in the non-coding ATXN8OS
transcript (Moseley et al. 2006). In tissue samples from both individuals affected
with SCA8 and from mice engineered to express the ATXN8OS transcript
containing expanded CUG repeats, ATXN8OS transcripts with expanded CUG
repeats were observed in ribonuclear inclusions. Interestingly, MBNL1 was also
localized in these inclusions in specifically the molecular layer interneurons and
deep cerebellar nuclei (Daughters et al. 2009).
Fragile X-associated tremor/ataxia syndrome
MBNL1 has been found in nuclear inclusions specific to Fragile Xassociated tremor/ataxia syndrome (FXTAS), which is another late onset
neurodegenerative disease. FXTAS affects the cerebellum and white matter of
the brain. In males, there is a 1 in 3,000 lifetime risk of developing FXTAS,
although the incidence of the causative mutation is higher (Jacquemont et al.
2004). The causative mutation is an expanded CGG repeat in the 5’UTR of the
FMR1 gene. When this trinucleotide is repeated more than 200 times, it leads to
loss of FMR1 expression and to fragile X syndrome, a more severe condition
than FXTAS. However, when the CGG trinucleotide is repeated 55 to 200 times
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(normal repeat number is 5 to 40), it can lead to FXTAS. This intermediate
number of CGG repeats leads to an increase in the level of FMR1 mRNA,
although there are normal to reduced levels of the FMR1 protein (Hagerman et
al. 2001; Hagerman and Hagerman 2015). A characteristic of FXTAS is the
presence of ubiquitin positive nuclear inclusions in neurons and astrocytes. In
samples from FXTAS patients, these inclusions were isolated and mass
spectrometry analysis found, among other proteins, the presence of MBNL1 and
the RNA binding protein HNRNPA2/B1 (Iwahashi et al. 2006). In FXTAS patient
brain samples these repeat expansion containing FMR1 transcripts co-localized
with the RNA binding proteins SAM68, HNRNPG and MBNL1 in nuclear foci.
However, in this study MBNL1 retained some ability to regulate the splicing of
some of its targets (Sellier et al. 2010). Therefore, although the role of MBNL1 in
myotonic dystrophy has been the most extensively studied, MBNL1 may also
play a role in other human genetic diseases.
CHAPTER 2. MBNL1 and Breast Cancer Progression
1. Identification of MBNL1 as a suppressor of breast cancer progression
The effect of MBNL1 on breast cancer metastasis was originally examined
because MBNL1 was a candidate miR-335 target transcript. MiR-335 has been
identified as a suppressor of breast cancer metastasis (Tavazoie et al. 2008).
The MBNL1 transcript has a miR-335 complementary site in its 3’UTR, however,
overexpression of miR-335 in breast cancer cells did not modulate the level of
MBNL1 protein (Figure 2.1A). Therefore, the seed sequence complementarity of
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miR-335 to the MBNL1 transcript is not sufficient to repress MBNL1 expression in
these cells. Although MBNL1 levels were unaffected by miR-335 overexpression
in breast cancer cells, the effect of MBNL1 on breast cancer metastasis was
tested. To assay the effect of MBNL1, a xenograft mouse model was used. In this
assay, RNAi-mediated depletion of MBNL1 using two independent short hairpin
RNAs (shRNAs) robustly increased the metastatic colonization capacity of MDA231 human breast cancer cells in tail-vein metastatic colonization assays (Figure
2.1B). Moreover, depletion of MBNL1 also significantly enhanced (~15-fold)
metastatic colonization by highly metastatic LM2 cells, which is an in vivo
selected sub-population of the MDA-231 cell line (Minn et al. 2005) (Figure 2.1C).
To test if the effect of MBNL1 on metastasis was cell line specific, the effect of
MBNL1 knockdown on the metastatic capacity of CN34 cells was tested. The
CN34 cell line is an independent and minimally passaged human breast cancer
cell line (Tavazoie et al. 2008). Again, MBNL1 knockdown in this independent cell
line significantly increased (~100-fold) lung colonization by the CN34 breast
cancer cells (Figure 2.2A). These findings reveal that endogenous MBNL1 can
act as a suppressor of breast cancer metastatic colonization.
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Figure 2.1 MBNL1 identification and effect on metastatic lung colonization
(A) Schematic depicting the miR-355 complementary site in the 3’UTR of the
MBNL1 transcript. Western blot for MBNL1 in whole cell lysate from LM2 breast
cancer cells overexpressing miR-335. Tubulin was used as a loading control. (B)
1 x 105 MDA-231 cells expressing either of two independent shRNAs targeting
MBNL1 or a control shRNA were intravenously injected into NOD-Scid mice.
Lung colonization was assessed by bioluminescence imaging and histology at
indicated timepoints. Representative H&E-stained lungs shown correspond to
day 83 post-injection. N=10-11. (C) 2 x 104 LM2 cells expressing an shRNA
targeting MBNL1 or a control shRNA were intravenously injected into NOD-Scid
mice and lung colonization was monitored by bioluminescence imaging.
Representative H&E and vimentin stained lungs correspond to day 64 postinjection. N=5.
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As injection of cancer cells into venous circulation primarily tests their capacity to
colonize the lung, the impact of MBNL1 depletion on systemic metastasis to
multiple organs was tested next. This was accomplished through intra-cardiac
injection of cancer cells into the arterial systemic circulation of immunodeficient
mice, which allows the cancer cells to pass through many organs before going
through the lungs. This assay revealed a significant increase in the colonization
of multiple distal organs, including brain, lung, and bone, by MBNL1 depleted
cells relative to control cells (Figure 2.2C). This was interesting as these organs,
as well as the liver, are the preferred sites of metastatic colonization of human
breast cancers (Lee 1983). The effect of MBNL1 overexpression on lung
metastatic colonization was also assayed. Overexpression of MBNL1 in highly
metastatic LM2 cells significantly decreased their lung colonization capacity
(Figure 2.2B). Together, these experiments show that MBNL1 is a robust
suppressor of breast cancer metastasis to multiple distal organs.
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Figure 2.2 MBNL1 suppresses breast cancer metastatic lung colonization
(A) 7.5 x 104 CN34 cells expressing either an shRNA targeting MBNL1 or a
control shRNA were intravenously injected into NOD-Scid mice and lung
colonization was monitored by bioluminescence imaging. Representative
vimentin stained lungs shown correspond to day 78 post-injection. N=6. (B)1 x
105 LM2 cells stably expressing exogenous MBNL1 or a control vector were
injected intravenously into NOD-Scid mice, lung colonization was monitored by
bioluminescence imaging. Representative H&E and vimentin stained lungs
shown correspond to day 37 post-injection N=10. (C) After intracardiac injection
into athymic nude mice of 5 × 104 MDA-231 cells expressing a control hairpin or
an shRNA targeting MBNL1, systemic metastasis was monitored over time by
bioluminescence imaging. N=10. Bioluminescence signal quantification and
gross bone histology corresponding to bone metastasis by 5 × 105 MDA control
cells or MBNL1 knockdown cells 35 days after intracardiac injection of the cells.
N=10.
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2. Expression and clinical correlation of MBNL in breast cancer
To test if an association exists between MBNL transcript levels and clinical
outcome in breast cancer patients, clinical data and microarray analysis of
primary tumors from breast cancer patients were analyzed. This analysis
revealed that there was a significant correlation between reduced MBNL1
transcript levels in tumors and elevated metastatic relapse rates (Figure 2.3B).
Furthermore, breast cancer metastases expressed significantly lower levels of
MBNL1 transcript relative to primary tumors (Figure 2.3A). However, there was
no significant correlation between MBNL2 or MBNL3 transcript levels and distant
metastasis free survival (Figure 2.3 C,D) (Gyorffy et al. 2010). Together, these
data reveal a clinical association between MBNL1 expression and metastasisfree survival in breast cancer patients. The two other human MBNL proteins,
MBNL2 and MBNL3 do have high sequence similarity to MBNL1. However,
MBNL1 is the most abundant MBNL transcript in breast cancer tumors, as
assessed by RNA sequencing data from The Cancer Genome Atlas (TCGA)
collection (Figure 2.3E). Therefore, it is reasonable that MBNL1 might play the
dominant role in mediating MBNL family protein effects on breast cancer
progression. Furthermore, in the cell lines used in this study, MBNL1 depletion by
RNAi did not downregulate MBNL2 transcript levels (Figure 2.3F), therefore
MBNL1 depletion alone is sufficient for the effects observed on metastasis
suppression.
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Figure 2.3 Expression and clinical correlation of MBNL in breast cancer
(A) Dot-plot representation of MBNL1 expression in a set of 117 primary breast
cancers and 36 distal metastases from previously published datasets. Cancer
samples were transcriptomically profiled using a common platform, and
normalized to allow for intra and inter-cohort comparisons. N=153. (B-D) KaplanMeier survival curves depicting probability of distant metastasis free survival
(DMFS) for breast cancer patients with tumors expressing high (red) or low
(black) levels of each indicated MBNL family member transcript. High and low
expression levels of each transcript were determined by dividing at the median.
N=1609. P-value is based on the Mantel-Cox log-rank test. (E) MBNL family RNA
levels (RPKM) in a set of breast tumors from RNA sequencing data (TCGA).
N=1098. (F) Relative MBNL1 and MBNL2 transcript levels in MDA-231 shCTRL
and shMBNL1 cells as assessed by qRT-PCR. HPRT1 was used as an
endogenous control. P-values based on a two-way Student’s t-test. Data are
shown as mean ±SEM .
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3. Effect of MBNL1 on metastasis-associated cellular phenotypes
Next, to define the cellular phenotypes altered in cells depleted of MBNL1,
assays for a variety of metastasis-associated phenotypes were carried out. To
test if cell proliferation was a major contributor to the enhanced metastatic
colonization observed upon MBNL1 depletion, cell count assays were carried out.
The viable number of cells was counted at five days post plating. ShRNAmediated knockdown of MBNL1 did not enhance in vitro cell proliferation.
Instead, MBNL1 depletion reduced the number of cells in vitro (Figure 2.4A).
Furthermore, MDA-231 cells depleted of MBNL1 did not exhibit enhanced
primary tumor growth rates in vivo (Figure 2.4B). Therefore, the enhanced in vivo
metastasis phenotype exhibited by MBNL1 depleted cells is unlikely to be caused
by increased proliferation or growth rates.
To identify potential phenotypes exhibited by MBNL1 depleted cells that could
enhance metastatic activity, the ability of breast cancer cells depleted of MBNL1
to invade through matrigel was analyzed. This transwell matrigel invasion assay
is a commonly used model of cancer cell invasion through the basement
membrane. The major components of matrigel are laminin, entactin and collagen
IV, all major structural proteins of the basement membrane (Hughes et al. 2010).
Invasion through matrigel was significantly enhanced in cells depleted of MBNL1
relative to control cells in both MDA-231 and CN34 breast cancer cell populations
(Figure 2.4E,G). Furthermore, this increase in invasiveness was abrogated upon
stable overexpression of MBNL1 in cells depleted of MBNL1 (Figure 2.4F).
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Another phenotype required for efficient metastasis to organs such as lung or
brain, which contain endothelial barriers, is enhanced trans-endothelial migration
capacity (Reymond et al. 2013). To assay this, a monolayer of human umbilical
vein endothelial cells (HUVECs) was formed on a transwell insert, and cancer
cells were seeded on top of the HUVEC monolayer. The number of cancer cells
migrating through the HUVEC monolayer was then quantified. This assay found
that cancer cells depleted of MBNL1 displayed enhanced trans-endothelial
migration capacity relative to control cells (Figure 2.4D). Importantly, MBNL1
depletion did not enhance general migratory capacity of cancer cells in the
absence of matrigel or endothelial cells as a barrier (Figure 2.4C). These results
reveal that MBNL1 impedes both the invasion and trans-endothelial migration
capacity of MDA-231 breast cancer cells, and suggests that these processes,
fundamental to metastatic progression, contribute to the in vivo metastasis
suppressive role of MBNL1.
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Figure 2.4 Effect of MBNL1 on cell proliferation, migration, transwell invasion
and trans-endothelial migration
(A) Cell proliferation of MDA-231 cells expressing shRNAs targeting MBNL1 or a
control shRNA was assessed by seeding 2.5 × 104 cells and quantifying the
viable number of cells after five days. N=3. (B) 5x105 MDA-231 cells expressing
an shRNA targeting MBNL1 or a control shRNA were inject into bilateral
mammary fat pads of NOD-Scid mice. Once palpable, tumor size was assessed
by caliper measurements. (C) Cell migration capacity of MDA-231 MBNL1knockdown cells compared to control cells was assessed by seeding 5 × 104 cells
in a boyden chamber with 0.8um pores. After 12 hours, the number of cells
migrated to the basal side of each insert was quantified. N=6-7. (D) Transendothelial migration capacity of MDA-231 cell with MBNL1 knockdown
compared to control cells was assessed by seeding 5 × 104 cells on a trans-well
insert with 0.3um pores coated with a monolayer of HUVECs. After 12 hours, the
number of cells migrating through the HUVEC monolayer was quantified by
counting the number of cells on the bottom side of each insert. N=6. (E) MDA231 cells with MBNL1 knockdown or control cells were seeded at 5 × 104 cells
per matrigel-coated insert with 0.8m pores. After 20 hours, the number of cells
invaded onto the basal side of each insert was quantified. N=12-13. (F) MDA-231
cells with MBNL1 knockdown and stable overexpression of the MBNL1 open
reading frame were subjected to transwell invasion assays. N=5. (G) Transwell
invasion assays were performed using CN34 cells with MBNL1 knockdown or
control cells. N=5-6. For all, p-values based on a two-way Student’s t-test. Data
are shown as mean ±SEM .
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CHAPTER 3: IDENTIFICATION AND ANALYSIS OF DIRECT MBNL1-RNA
INTERACTIONS
1. Using HITS-CLIP to identify MBNL1-bound RNAs in breast cancer cells
Given that MBNL1 is an RNA binding protein, and to further investigate the
molecular mechanism by which MBNL1 mediates metastasis suppression, high
throughput sequencing-crosslinking immunoprecipitation (HITS-CLIP) was
performed to identify RNAs that directly interact with MBNL1 in breast cancer
cells (Figure 3.1A). These MBNL1-interacting RNAs were potential mediators of
the metastasis suppressive effects of MBNL1, as RNAs bound by MBNL1 may
also be directly regulated by MBNL1. HITS-CLIP is used to identify endogenous
RNA targets of RNA binding proteins and uses ultra-violet crosslinking on whole
cells or tissues to capture in vivo RNA binding protein-RNA interactions
(Licatalosi et al. 2008). Analysis of the MBNL1 HITS-CLIP sequencing library was
carried out using the CIMS algorithm, which incorporates information provided by
the crosslink-induced nucleotide deletions present at the site of RNA-protein
interaction, a mutation type that is a consequence of the UV radiation used to
crosslink RNA and proteins in the HITS-CLIP procedure (Zhang et al. 2011).
Using this program, statistically significant MBNL1-bound regions were identified,
and FIRE (Elemento et al. 2007), a computational method based on mutual
information, was used to find any enriched nucleotide motifs in those clusters.
This analysis found that MBNL1-bound CLIP tag clusters were significantly
enriched for the GCUU motif (Figure 3.1B), which is in agreement with the YGCY
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motif previously determined as the optimal MBNL1 binding motif by SELEX
(Goers et al. 2010). This finding is also in agreement with data from HITS-CLIP
for MBNL1 in mouse myoblasts, where MBNL1 binding sites were found to be
enriched for UGC and GCU containing 4mers (Wang et al. 2012). Analysis of the
relative genic distribution of MBNL1 binding sites revealed that, as expected from
its known role as a regulator of alternative splicing, the majority of MBNL1
binding sites occurred in introns. However, MBNL1 interacted with many sites in
coding and untranslated regions (Figure 3.1C), consistent with recent findings
from HITS-CLIP studies of MBNL1 in mouse myoblasts (Masuda et al. 2012;
Wang et al. 2012).
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Figure 3.1 HITS-CLIP of MBNL1 in breast cancer cells
(A) 32P-labeled RNA-MBNL1 complexes were visualized by autoradiography after
treatment with low or high concentrations of RNase, and immunoprecipitation
with anti-MBNL1 or IgG and separation by SDS-PAGE. Western blot for MBNL1
in equal volumes of lysate used for MBNL1 HITS-CLIP before (input) and after
(IP sup) immunoprecipitation with MBNL1 antibody or IgG conjugated beads. (B)
Nucleotide motifs significantly enriched in the MBNL1 bound HITS-CLIP CIMS
clusters. (C) Pie chart depicting percent of MBNL1 HITS-CLIP clusters mapping
to the indicated genic regions.
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2. Analysis of MBNL1-regulated alternative splicing events in breast cancer
cells
MBNL1 has been well characterized as a regulator of alternative splicing
(Pascual et al. 2006; Wang et al. 2012). Therefore, the effect of MBNL1 depletion
on alternative splicing in breast cancer cells was examined. To do this, highthroughput transcriptome sequencing was carried out in MDA-231 cells stably
expressing a control shRNA or expressing two independent MBNL1-targeting
shRNAs. The computational tool MISO (Katz et al. 2010), a program that infers
relative levels of transcript isoforms using RNA sequencing data, was then used
to identify MBNL1-dependent changes in transcript isoforms in breast cancer
cells. Alternative exons that had MBNL1-dependent changes in abundance were
identified by MISO analysis of RNA sequencing data. These were then compared
with the MBNL1 HITS-CLIP data set to obtain a set of transcripts that had
MBNL1-dependent differences in exon inclusion and were also bound by MBNL1
in the HITS-CLIP data, and therefore likely to be directly regulated by MBNL1
binding. The criteria used to arrive at this set of MBNL1-dependent alternative
exons was that the event had a bayes factor of ≥10 and a change in the percent
spliced in exon (ΔΨ) of ≥|0.2| in each of the two independent MBNL1-targeting
shRNA expressing cell lines compared to the control cell line, as assessed by
MISO (Table 3.1).
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This analysis revealed 21 MBNL1-dependent alternative exons that were in
transcripts also bound by MBNL1, with 71% of these exons exhibiting inclusion
and the remainder exhibiting exclusion upon MBNL1 knockdown. Transcripts that
had MISO predicted MBNL1-dependent changes in exon inclusion and had
MBNL1 HITS-CLIP binding sites were validated by RT-PCR. Although many of
the MISO-predicted transcript variants were validated by RT-PCR, several did not
validate. In these cases, only one of the predicted transcript variants was
detected by RT-PCR. However, of the genes that had detectable levels of both
MISO-predicted transcript variants by RT-PCR analysis, there was good
correlation between the MISO calculated ΔΨ and the ΔΨ assessed by RT-PCR
(Figure 3.2B).
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Figure 3.2 MBNL1-dependent skipped exons
(A) MBNL1 interacts with sites near MBNL1-skipped exons. For the indicated
transcripts, the skipped exon and its upstream and downstream intron and exon
are shown, with mapped reads from experimental replicates of MBNL1 HITSCLIP. (B) Correlation plots of ΔΨ values calculated by MISO compared to ΔΨ
values calculated by semi-quantitative RT-PCR for MBNL1-dependent alternative
exons for genes that had both transcript forms expressed as assessed by RTPCR. Shown are separate plots for each independent MBNL1-targeting shRNA
compared to shCTRL. Pearson correlation coefficient is shown for each plot.
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This analysis found four genes, FGFR1 (fibroblast growth factor receptor 1),
SEC31A (SEC31 homolog A), MYL6 (myosin light chain 6), and PICALM
(phosphatidylinositol binding clathrin assembly protein) that had large (> 30%)
changes in exon exclusion in MBNL1-knockdown cells compared to control cells
by both MISO and by RT-PCR analysis, and were bound by MBNL1 (Table 3.1,
Figure 3.2A, Figure 3.3A). Two of these transcripts, FGFR1 and SEC31A,
exhibited increased inclusion of a specific exon when MBNL1 was depleted. Two
others, MYL6 and PICALM, displayed increased exclusion of an exon upon
MBNL1 depletion. Furthermore, in MDA-231 cells expressing a MBNL1-targeting
shRNA, overexpression of MBNL1 resulted in the reversion of these splice forms
(Figure 3.3 A). MBNL1-dependent changes in relative transcript isoform
abundance were then tested to see if they could affect the transwell invasion
phenotype observed in MBNL1 depleted cells. In this set of experiments, the
transcript variant that had an increase in exon inclusion was specifically depleted
using siRNA. For the transcripts that had an increase in exon inclusion upon
MBNL1 knockdown (FGFR1, SEC31A), these longer isoforms were
experimentally depleted using siRNA in MBNL1 knockdown cells. Conversely,
MYL6 and PICALM had decreased exon inclusion in MBNL1 knockdown cells,
and therefore their longer isoforms were depleted using siRNA in shCTRL cells.
The modulation of these transcript isoforms in these cells lines did not have
significant effect on the transwell invasion capacity of the cells (Figure 3.3B).
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Figure 3.3 Semi-quantitative RT-PCR analysis of MISO-predicted MBNL1dependent alternative splicing events and effect on in vitro invasion
(A) Semi-quantitative RT-PCR analysis of MBNL1-dependent transcript isoforms
predicted by MISO in RNA-seq data. Shown are RT-PCR products visualized by
agarose gel analysis. Percent exon inclusion relative to shCTRL or to MBNL1
overexpressing cells was calculated using Image J. Cartoons represent the exon
included (contains the red exon) and the skipped exon forms of each indicated
transcript, with the DNA length in basepairs indicated for each transcript variant.
(B) MDA-231 cells expressing shCTRL or sh1MBNL1 were transiently transfected
with siRNAs targeting the MBNL1-dependent exon of the indicated transcript.
Transwell invasion assays were then carried out. N=6. Data are shown as mean
±S.E.M.
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This result does not exclude the possibility that regulation of alternative splicing
by MBNL1 contributes to invasion and metastasis. However, in the analysis of
the group of transcripts identified here, of those that had both direct MBNL1dependent differences in transcript isoform expression and the greatest changes
in isoform expression, none individually affected the invasion capacity of MDA231 breast cancer cells.
CHAPTER 4. MBNL1 REGULATION OF TRANSCRIPT STABILITY AND
IDENTIFICATION OF MBNL1-STABILIZED METASTASIS SUPPRESSOR
TRANSCRIPTS
1. Analysis of MBNL1 effect on global transcript stability
A major type of regulatory activity for RNA binding proteins is control of
transcript stability. There is some evidence that MBNL1 levels can modulate the
stability of transcripts in mouse myoblasts (Masuda et al. 2012), but the effect of
MBNL1 on transcript stability in breast cancer cells has not been reported.
Therefore, to determine if MBNL1 depletion alters the stability of transcripts to
which it binds, a transcriptome-wide analysis of RNA stability was conducted. In
this experiment, breast cancer cells with MBNL1 depleted or control cells, were
treated with alpha-amanitin to inhibit polymerase II-dependent transcription, and
RNA was isolated. Relative transcript levels were determined by transcriptomic
profiling. Relative distribution of MBNL1-bound transcripts in the stability dataset
was assessed using TEISER (Goodarzi et al. 2014). This analysis showed that
MBNL1-bound transcripts were enriched among transcripts that had decreased
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stability upon MBNL1 knockdown (Figure 4.1A). This is consistent with a model
where MBNL1-bound transcripts are stabilized by MBNL1 binding.
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Figure 4.1 Identification of MBNL1-stabilized transcripts
(A) Differential stability of transcripts in MDA-231 MBNL1-depleted compared to
control cells as assessed by alpha-amanitin treatment and microarray profiling.
Transcripts were ordered by their log2 fold-change in MBNL1-knockdown cells
compared to control cells at nine hours after alpha-amanitin treatment normalized
to pre-alpha-amanitin treated transcript levels. MBNL1-bound transcripts, as
assessed by HITS-CLIP, were significantly enriched among transcripts
destabilized by MBNL1-knockdown. (B) Venn diagram of transcripts stabilized
and bound by MBNL1. (C) qRT-PCR of candidate MBNL1 target transcripts in
MDA-231 shMBNL1 and shCTRL cells at steady-state. HPRT1 was used as an
endogenous control. N=3. (D) qRT-PCR of putative MBNL1 target transcripts in
CN34 shMBNL1 and shCTRL cells at steady-state. HPRT1 was used as an
endogenous control.
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Next, the identification of genes directly bound and regulated by MBNL1
that also mediate MBNL1’s effects on metastasis was carried out. To do this,
transcripts that were directly bound by MBNL1 in the HITS-CLIP dataset, were
stabilized by MBNL1 based on the alpha-amanitin analysis, and had reduced
steady-state abundance upon MBLN1 knockdown, were identified. This analysis
identified a group of seven transcripts as potential regulators of breast cancer
metastasis downstream of MBNL1 (Figure 4.1B). The steady-state levels of
these transcripts were assessed by qRT-PCR in MBNL1-knockdown compared
to control cells in the MDA-231 and CN34 cancer cell lines. Three of these
transcripts exhibited reduced steady-state levels upon MBNL1 knockdown in both
cell lines and using two independent MBNL1-targeting shRNAs: DBNL, TACC1
and TK1 (Figure 4.1C,D). The reduced stability of these transcripts after alphaamanitin treatment and upon MBNL1-depletion in MDA-231 and CN34 cells was
verified by qRT-PCR (Figure 4.2A,B). The stabilization of these transcripts by
MBNL1 was also tested using an independent method of transcription inhibition.
In this assay, dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), an inhibitor of
CDK9, was used to inhibit transcription. Breast cancer cells were treated with
DRB and RNA was isolated at various time-points for qRT-PCR analysis. DBNL,
TACC1, and TK1 transcripts exhibited shorter half-lives in MBNL1-depleted cells
relative to control cells, while COL6A1, IGFBP4 and VIPR1 transcripts did not
exhibit significant changes in decay rates in MBNL1-depleted cells relative to
control cells in this assay (Figure 4.2C). These findings demonstrate that, in
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breast cancer cells, MBNL1 depletion reduces the stability of a subset of
transcripts to which it binds.

Figure 4.2 Validation of MBNL1-dependent transcript stability
qRT-PCR of putative MBNL1 target transcripts in (A) MDA-231 and (B) CN34
shMBNL1 and shCTRL cells after nine hours of alpha-amanitin treatment. 18S
was used as an endogenous control. N=3. (C) qRT-PCR of putative MBNL1
target transcripts in MDA-231 shMBNL1 and shCTRL cells at times indicated
after treatment with DRB. N=3. For all, P-values are from a one-way Student’s ttest. Data are shown as mean ±S.E.M.
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2. Effects of DBNL and TACC1 on metastatic invasion in breast cancer
cells
MBNL1 depletion leads to the reduced stability and subsequently the
reduced abundance of DBNL, TACC1 and TK1 transcripts. To test if rescuing the
expression of these genes in cells depleted of MBNL1 could reverse the
enhanced metastatic phenotype observed, each of these genes was stably
overexpressed in MBNL1-depleted cells, using overexpression of mCherry as a
control gene. These cells were then subjected to in vitro transwell invasion
assays, and a significant decrease was observed in the invasion capacity of the
cell lines overexpressing DBNL and TACC1 relative to cells expressing mCherry
control (Figure 4.3A). However, TK1 over-expression in this context did not
significantly reduce the invasiveness of MBNL1-depleted cells. As DBNL and
TACC1 overexpression could both compensate for MBNL1-knockdown in
transwell invasion assays, elucidating the roles of DBNL and TACC1 in
repressing invasion and metastasis downstream of MBNL1 was the next step.
Also, and consistent with these findings, overexpressing DBNL and TACC1 in the
CN34-Lm1a line, an independent highly metastatic breast cancer cell population,
also suppressed cell invasiveness (Figure 4.3B).
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Figure 4.3 Effect of DBNL and TACC1 on invasion and metastatic lung
colonization
(A) Candidate MBNL1-regulated genes were stably overexpressed in shMBNL1
MDA-231 cells. mCherry was overexpressed as a control. 5x104 cells were
seeded in transwell matrigel invasion chambers and the number of cells invading
to the basal side of the insert was quantified after 20 hours. N=6. (B) CN34-LM1a
cells stably overexpressing DBNL, TACC1 or mCherry were assessed for
transwell invasion capacity. N=6. (C) 2x104 MDA-231 cells stably overexpressing
DBNL, TACC1 or mCherry were injected into the venous circulation of NSG mice.
Lung colonization was monitored by bioluminescence imaging. N=6. Western blot
showing levels of DBNL and TACC1 in whole cell lysate from MDA-231
sh1MBNL1 cells stably overexpressing the indicated factors. Data are shown as
mean ±SEM.
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To determine if these genes impacted metastatic lung colonization in vivo,
breast cancer cell with shRNA-mediated stable MBNL1 knockdown were
engineered to stably overexpress DBNL, TACC1 or mCherry. These cells were
injected into the venous circulation of immunodeficient mice. Overexpressing
DBNL and TACC1 in MBNL1-depleted cells significantly abrogated the enhanced
metastatic phenotype conferred by MBNL1 depletion (Figure 4.3C). These
findings demonstrate that overexpression of either DBNL or TACC1 is sufficient
to repress the metastatic lung colonization of MBNL1-depleted breast cancer
cells in vivo, as well as to suppress transwell invasion in vitro.
One commonly used mechanism of regulating mRNA stability is
alternative poly(A) site choice (APA), which leads to 3’UTR length alterations.
Both DBNL and TACC1 have extensive binding of MBNL1 in their 3’UTRs, a
location which could control poly(A) site selection (Figure 4.4A). The length of the
3’UTRs of DBNL and TACC1 were assessed by qRT-PCR, using primers specific
to different part of these 3’UTRs. In this analysis, both DBNL and TACC1 3’UTR
lengths were unchanged upon MBNL1 depletion (Figure 4.4B,C).

61

Figure 4.4 MBNL1 binding on 3’UTRs of DBNL and TACC1 and 3’UTR length
(A) MBNL1 interacts with the 3’UTRs DBNL and TACC1. The last exon of the
indicated transcripts are shown with mapped reads from experimental replicates
of MBNL1 HITS-CLIP. (B) qRT-PCR analysis of DBNL and (C) TACC1 3’UTR
length in MDA-231 cells with stable knockdown of MBNL1 or cells expressing a
control shRNA. 3’UTR primers are numbered as increasingly distal from the stop
codon. N=3. Data are shown as mean ±S.E.M.
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As poly(A) tail length is a major determinant of mRNA stability, the relative
poly(A) tail lengths of DBNL and TACC1 were assessed. To do this, a method
employing 3’ tagging of adenylated transcripts and subsequent PCR amplification
of the poly(A) tail using transcript specific primers, was carried out (Janicke et al.
2012). This assay revealed no difference in the poly(A) tail length of DBNL and
TACC1 transcripts upon MBNL1 depletion (Figure 4.5A-D). This result suggested
that MBNL1 does not regulate the stability of these transcripts through controlling
their adenylation or deadenylation. These data are consistent with MBNL1
binding to the 3’UTRs of DBNL and TACC1 and regulating their stability in a
poly(A) tail length- and APA- independent manner.
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Figure 4.5 Poly(A) tail length of DBNL and TACC1 transcripts
The poly(A) tail length of DBNL and TACC1 transcripts was assessed in MDA231 shCTRL and MBNL1 knockdown cells as described in methods. The PCR
products were run on a 2% agarose-TAE gel and stained with ethidium bromide.
(A,B) DBNL poly(A) tail length using two independent gene-specific primers
(DBNL-1, DBNL-2). (C,D) TACC1 poly(A) tail length using two independent genespecific primers (TACC1-1, TACC1-2).
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3. Clinical correlation of DBNL and TACC1 in breast cancer outcome
TACC1 expression can be inferred from affymetrix microarray datasets as
this transcript is represented by an informative probe. Analysis of a large dataset
comprising 3455 tumor samples representing multiple cohorts revealed a
significant correlation between TACC1 expression and relapse-free survival in
breast cancer patients (Figure 4.6A), a finding consistent with TACC1 acting as a
suppressor of breast cancer metastasis. However, DBNL is not represented by a
probe on the microarray platform used to analyze these large breast cancer
datasets. Therefore, to determine whether there exists an association between
DBNL and breast cancer progression, qRT-PCR was performed on a panel of
publicly available cDNAs (Origene) generated from breast tumor-derived RNA.
Consistent with it having a metastasis suppressor role, metastatic stage IV
tumors expressed significantly lower levels of DBNL relative to stage I and stage
II tumors (Figure 4.6B).
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Figure 4.6 Clinical correlation of DBNL and TACC1 expression in breast cancer
(A) Kaplan-Meier curve showing relapse free survival of breast cancer patients
with tumors expressing high (red) or low (black) levels of the TACC1 transcript.
N=3455. (B) Levels of DBNL were assessed by qRT-PCR from RNA obtained
from a panel of staged breast cancer tumors. Beta-actin was used as an
endogenous control. N=48. (C) qRT-PCR for MBNL1 and TACC1 in MDA-231
cells stably expressing two independent TACC1-targeting shRNAs, HPRT1 was
used as an endogenous control. P-values are based on Student’s t-test unless
otherwise noted. Data are shown as mean ±SEM.
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Interestingly, data suggests that MBNL1 is upstream of TACC1 in this regulatory
relationship, as shRNA-mediated depletion of TACC1 did not affect MBNL1
transcript levels in MDA-231 cells (Figure 4.6C). However, MBNL1 could
conceivably be regulated at the transcriptional level by TACC1, as TACC1 has
been shown to have effects on the transcriptional activity of the retinoic acid
receptor alpha and thyroid receptor, and also interacts with YEATS4/GAS41,
which is part of a complex that acetylates histones (Guyot et al. 2010; Lauffart et
al. 2002). Together, this data is consistent with MBNL1 interacting with TACC1
and DBNL transcripts to stabilize them, thereby suppressing invasion and
metastasis of MDA-231 breast cancer cells. DBNL expression is reduced in stage
IV breast cancer compared to stage I and stage II tumors. TACC1 transcript
levels are positively correlated with significantly longer relapse-free survival of
breast cancer patients, suggesting that TACC1 acts as a breast cancer
metastasis suppressor in human breast cancers.
4. Effect of secreted proteins on MBNL1-mediated phenotypes
Cancer cells secrete factors that are known to regulate their spread from a
primary tumor and to promote colonization of distant organs. As MBNL1
depletion enhanced in vitro invasion and trans-endothelial migration, and both of
these processes can be modulated by cancer cell-mediated secretion of
molecules into the extracellular environment, it seemed an intriguing possibility
that MBNL1 might regulate the expression levels of secreted pro-metastatic
molecules. A study in mouse myoblasts has also found a role for MBNL protein
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localization of transcripts that contain a signal peptide sequence (Wang et al.
2012). To test the possibility that MBNL1 depletion impedes the invasion capacity
of breast cancer cells through regulation of secreted factors, the invasion
capacity of cells treated either with media that had been conditioned by MBNL1depleted cells or with media that had been conditioned by cells expressing a
control shRNA was assessed. In this assay, breast cancer cells seeded in
conditioned media from MBNL1-depleted cells displayed significantly greater
invasion capacity relative to cells seeded in conditioned media from control cells
(Figure 4.7A). This finding suggested that factors specifically secreted by
MBNL1-depleted cells could contribute to the increased cell invasiveness.
To identify any molecule(s) regulated by MBNL1 that also mediated this
pro-invasive effect, stable isotope labeling by amino acids in cell culture (SILAC)
and mass spectrometry (MS) was conducted to identify proteins with different
levels in media conditioned by control or MBNL1-depleted cells. This experiment
revealed five proteins with higher abundance in MBNL1-depleted cell conditioned
media relative to control cell conditioned media. These proteins are CTGF,
LOXL2, QSOX1, APLP2 and NPC2 (Table 4.1). Three of these factors, CTGF
(connective tissue growth factor), LOXL2 (lysyl oxidase-like 2), and QSOX1
(quiescin Q6 sulfhydryl oxidase 1), have been previously implicated in cell
migration and invasion. LOXL2 and QSOX1 have also been associated with
breast cancer progression (Ahn et al. 2013; Barker et al. 2011; Chen et al. 2007;
Katchman et al. 2013).
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Figure 4.7 Identification of secreted proteins upregulated by MBNL1 depletion
(A) Conditioned media from MDA-231 cell with MBNL1 knockdown or shCTRL
cells was used to treat MDA-231 shCTRL cells that were subjected to transwell
invasion assays. N=5-6. (B) Western blot of conditioned media from MDA-231
and CN34 cells with MBNL1 knockdown or control cells, all in biological triplicate.
Bar graphs are quantitation of LOXL2 and QSOX1 signal from the Western blots.
(C) ELISA for CTGF in conditioned media from MDA-231 cells with MBNL1
knockdown or control cells. N=3. Data are shown as mean ±S.E.M.
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To validate the up-regulation of these proteins in conditioned media from MBNL1knockdown cells compared to control cell conditioned media, Western blotting for
LOXL2 and QSOX1 was carried out, while an ELISA was used to assay CTGF
levels (Figure 4.7B,C).
To assess if these factors could affect the invasion capacity of cells,
siRNA-mediated knockdown was used to deplete CTGF, LOXL2, and QSOX1
alone, as well as each of these transcripts in combination with the others.
Depletion of any one of these factors alone did not affect the invasive capacity of
breast cancer cells (Figure 4.8A). However, depletion of LOXL2 or QSOX1 in
combination with depletion of CTGF led to a decrease in the invasion capacity of
MDA-231 cells (Figure 4.8B). This data is consistent with a role for the secreted
factors LOXL2, QSOX1 and CTGF in mediating the effect of MBNL1 on breast
cancer cell invasion.
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Figure 4.8 Effect of secreted proteins on in vitro invasion
(A) MDA-231 cells depleted of MBNL1 in combination with CTGF, LOXL2 or
QSOX1 were subjected to transwell invasion assays. N=5-6. (B) MDA-231 cells
depleted of MBNL1 in combination with the indicated factors were subjected to
transwell invasion assays. N=6. Data are shown as mean ±S.E.M.
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CHAPTER 5. DISCUSSION
1. MBNL1 regulation of messenger RNA expression
This study identified MBNL1 as a suppressor of breast cancer
progression, and discovered that part of this effect is mediated by MBNL1
regulation of DBNL and TACC1 transcript stability. Interestingly, factors secreted
by MBNL1-depleted cells were found to moderately enhance cancer cell
invasion. The mechanism through which these secreted factors are upregulated
in MBNL1 depleted cells is presently unclear. MBNL1 was also found to directly
bind and regulate a set of alternatively spliced transcripts in breast cancer cells.
However, RNAi-mediated modulation of the levels of these transcript variants had
no significant effect on the in vitro invasion capacity of breast cancer cells. It is
possible that some of these MBNL1-dependant alternative transcript variants
contribute to the regulation of metastasis, but may work in concert with each
other so that modulation of a single splicing event does not have an effect on
invasion. Therefore, the primary mediator of MBNL1-mediated breast cancer
metastasis suppression identified in this study is the stabilization of a subset of
transcripts by MBNL1 binding (Figure 5.1)
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Figure 5.1 Model of MBNL1 regulation of transcript stability that contributes to
breast cancer metastasis
Depiction of MBNL1 binding to the 3’UTRs of DBNL and TACC1 to increase their
stability and thereby contribute the suppression of breast cancer cell invasion and
metastasis.
An open question is the mechanism by which MBNL1 affects the stability
of mRNAs in breast cancer cells. MBNL1 is known to affect pre-mRNA
processing by contributing to both alternative exon and alternative poly(A) site
selection. A recent study reported a regulatory role for MBNL proteins in
polyadenylation site choice on 3’UTRs in mouse embryonic fibroblasts, thereby
controlling 3’UTR length (Batra et al. 2014). However, in the current study, there
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was no observed difference in the 3’UTR length of DBNL and TACC1 transcripts
upon MBNL1 depletion, as assessed by qRT-PCR. There was also no observed
change in the length of the poly(A) tails of DBNL and TACC1 transcripts when
MBNL1 was depleted. These results suggest that APA and poly(A) tail
lengthening are not mechanisms through which MBNL1 regulates the stability of
these transcripts, although these regulatory mechanisms may be relevant to the
control of the stability of other MBNL1-stabilized transcripts.
One possibility for the mode of MBNL1 regulation of mRNA stability that is
consistent with this data is MBNL1-dependent localization of mRNAs to stress
granules and/or P-bodies. MBNL1 has been observed to localize to arseniteinduced stress granules in HeLa and COS-7 cells (Onishi et al. 2008). Cancer
cells undergoing the steps necessary for metastatic progression encounter
stresses that are known to induce stress granule formation, including hypoxia
and nutrient deprivation. It is possible that a function of MBNL1 in breast cancer
cells is to localize transcripts to stress granules, where they would be protected
from decay and then could rapidly resume translation upon removal of the stress.
Therefore, when MBNL1 is depleted these transcripts would be subjected to
increased degradation. Similarly, MBNL1 could bind transcripts in P-bodies to
protect them from decay. This would be a mechanism similar to one observed to
regulate the poly(A) tail length-independent stability of the HIF1A transcript via
binding by PAN2 (Bett et al. 2013). In this model for MBNL1 stabilization of
transcripts, MBNL1 would stabilize a subset of its mRNA targets by localizing
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them to cytoplasmic RNA granules where they would be protected from decay
factors.
2. Regulation of MBNL1 expression and activity
Little is known about the regulation of MBNL1 expression. The most direct
data addressing this question comes from studies in Drosophila, where it was
shown that MEF2 (myocyte enhancer factor 2) drives transcription of
muscleblind, and tissue-specific enhancer elements of muscleblind expression
were also identified, although these sequences are not conserved in humans
(Artero et al. 1998; Bargiela et al. 2014). Regulation of MBNL1 levels and activity
in cancer is a clinically relevant question because of MBNL1’s role in suppressing
breast cancer metastasis identified in this study. In breast cancer, there are many
possibilities for regulation of MBNL1 transcript levels. These include decreased
transcription of the gene through copy number loss at the MBNL1 genetic locus,
mutation or epigenetic silencing of promoter elements required for transcription of
MBNL1, or through the loss-of-function of transcription factors that transcribe the
MBNL1 gene. MBNL1 could also be down-regulated at the mRNA level through
the alteration of an as yet to be defined cis-regulatory element that controls
MBNL1 transcript stability, or through levels of a trans-acting factor that controls
MBNL1 transcript stability.
The clinical data available for examination in this study only contained
data for MBNL1 transcript levels, and levels of MBNL1 mRNA do correlate with
metastasis-free survival of breast cancer patients (Figure 2.3D). However,
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MBNL1 protein loss-of-function is another formal possibility for down-regulation of
MBNL1 activity. One mechanism for this would be the mutation of amino acids in
the MBNL1 protein that affected either its RNA binding ability or its interactions
with other proteins. Another interesting possibility is regulation of MBNL1 protein
activity by a toxic RNA gain-of-function mechanism. In this model, cancer cells
would have unchanged MBNL1 transcript and protein levels, but inhibition of
MBNL1 activity would occur through sequestration of the MBNL1 protein by an
RNA containing expanded CUG repeats, in a mechanism similar to that observed
in myotonic dystrophy. It is plausible that a subset of cancer cells could acquire
just such a trinucleotide repeat expansion, which would then lead to the
accumulation of a transcript with a large number of CUG repeats, which could
then bind MBNL1. Acquisition of expanded CAG trinucleotide repeats at multiple
loci in breast cancer has been observed (Pizzi et al. 2007). Therefore, it is
conceivable that such a mechanism could also generate CUG repeat expansions
in breast cancers. This could lead to the suppression of MBNL1 activity in cancer
cells and induce acquisition of enhanced metastatic capacity. Interestingly, a
higher incidence of primary tumor development in individuals affected with
myotonic dystrophy has been observed, and this increase seems to be specific to
the disease itself, as unaffected family members do not have an increased
cancer incidence (Gadalla et al. 2011; Lund et al. 2014; Win et al. 2012). There
are no reports on the relative incidence of metastatic disease in individuals with
myotonic dystrophy, but this would be an interesting area for future study. There
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have also been multiple case reports that have examined samples from
individuals with myotonic dystrophy who also had cancer of various types, and
found an expansion of the CUG repeat in the DMPK gene in tumor cells
compared to normal tissue (Akiyama et al. 2008; Banuls et al. 2004; Jinnai et al.
1999; Kinoshita et al. 1997; Kinoshita et al. 2002; Ogata et al. 1998; Osanai et al.
2000). This illustrates the fact that cancers that develop from a wide variety of
tissues have the ability to generate additional expansions in CUG repeats, which
could contribute to the down-regulation of MBNL1 and possibly increase the
metastatic capacity of the cancer cells.
3. Roles of DBNL and TACC1 in cancer progression
In this study, expression of DBNL and TACC1 counteracted the MBNL1depedent effects on cancer cell invasion and metastatic lung colonization. The
cell biological processes affected by DBNL and TACC1 could conceivably
mediate these phenotypes. A role for DBNL in suppressing breast cancer
metastasis has not been previously reported. DBNL (drebrin-like protein) is an Factin binding protein and has roles in mammalian development, endocytosis and
the immune response (Connert et al. 2006; Haag et al. 2012; Hepper et al. 2012;
Kessels et al. 2000; Larbolette et al. 1999; Schymeinsky et al. 2009). DBNL has
an N-terminal F-actin binding domain and C-terminal proline rich and SH3
domains. The DBNL SH3 domain has been reported to interact with factors
involved in endocytosis, cell motility, and neuronal morphology development
(Fenster et al. 2003; Hou et al. 2003; Kessels et al. 2001; Pinyol et al. 2007). In a
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mouse genetic knockout of DBNL, animals have adult onset organ abnormalities,
including enlarged spleens, dilation and fibrosis of heart chambers, and lung
emphysema. In adulthood, these animals also develop impaired motor skills,
which may be due to the observation that they have impaired synaptic vesicle
recycling of hippocampal boutons (Connert et al. 2006).
Although there is no reported role for DBNL in cancer progression, a
recent study showed that DBNL depletion in Src-transformed fibroblasts
regulates podosome rosette formation and, interestingly, increases cell
invasiveness (Boateng et al. 2012). Although this effect was observed in
transformed fibroblasts, this finding is consistent with decreased DBNL levels in
breast cancer cells enhancing their invasive capacity. Another process relevant
to metastasis, adhesion to blood vessel walls, has been shown to be affected by
DBNL in neutrophils. Intriguingly, DBNL has been shown to promote firm
neutrophil adhesion in vitro under physiologic shear stress conditions and to also
promote adhesion and extravasation in vivo. Depletion of DBNL resulted in a
reduced number of integrin-beta-2 clusters in high-affinity conformation.
Furthermore, DBNL was necessary for neutrophil crawling under flow conditions
(Hepper et al. 2012; Schymeinsky et al. 2009). Cancer cells go through a process
similar to this during extravasation. Reduction in the level of DBNL in breast
cancer cells, if consistent with the function of this protein in neutrophils, would
decrease adhesion and intraluminal crawling of a cancer cell. This could allow a
cancer cell to travel farther in the bloodstream and then only adhere to
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endothelial cells when physically forced to, such as arrest in small capillaries.
This decrease in adhesion might allow for a cancer cell to spread farther in the
body.
TACC1 (transforming acidic coiled-coil containing protein 1) is a member
of the TACC family, which also contains TACC2 and TACC3. All three of these
proteins are characterized by the presence of a highly conserved, highly acidic
200 amino acid long coiled-coil domain at their C-termini (Still et al. 2004).
Although the down-regulation of TACC1 has been previously reported in breast
cancer (Conte et al. 2003), the role of this molecule in mediating this process
remains undefined. TACC1 has been reported to associate with proteins involved
in diverse cellular processes, including those involved in cell division, specifically
mitotic spindle dynamics (chTOG/CKAP5, Aurora A, B and C), transcription
(GAS41/YEATS4, thyroid hormone receptor, retinoid acid receptor alpha, FHL3),
and RNA processing (LSM7, SNRPG, TDRD7) (Conte et al. 2003; Gabillard et al.
2011; Guyot et al. 2010; Lauffart et al. 2002; Lauffart et al. 2007). In adult
humans, transcript levels of TACC1 are highest in the brain, placenta, skeletal
muscle, spleen, testes, and uterus, and TACC1 levels are higher in the
developing mouse embryo than in adult mouse tissue (Lauffart et al. 2006). No
mouse genetic knockout model of TACC1 has been reported. Experiments to
assess the localization of TACC1 in HeLa cells found that during mitosis, TACC1
is present at the spindle midzone during anaphase, is localized at the midbody
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during cytokinesis, while during interphase TACC1 relocalizes to the nucleolus
(Delaval et al. 2004).
TACC1 was originally identified as a molecule involved in breast cancer
because the TACC1 gene is located on 8p11, a chromosomal region commonly
amplified in breast cancers. Furthermore, it was found that overexpression of
TACC1 in mouse fibroblasts resulted in cellular transformation and anchorage
independent growth, suggesting that TACC1 has a role in oncogenesis (Still et al.
1999). Additionally, ectopic overexpression of TACC1 in a mouse pten
heterozygous background increased the number of mammary tumors formed
(Cully et al. 2005). However, in contrast to this, TACC1 mRNA has been shown
to be down-regulated in breast tumors compared to normal breast tissue, which
supports a suppressive role for this molecule in breast cancer progression (Conte
et al. 2003). In agreement with this, analysis of patient data in this current study
revealed that TACC1 transcript levels are significantly correlated with relapsefree survival in breast cancer patients (Figure 4.2A). These data can be
explained if TACC1 acts as both a promoter of tumorigenesis but a suppressor of
cancer progression. Recently, rare but recurrent fusions of FGFR and TACC
genes have been reported in glioblastoma multiforme. Fusions of FGFR1-TACC1
and FGFR3-TACC3 were observed in a small subset of glioblastomas, with the
tyrosine kinase domain of the FGFR gene fused to the acidic coiled-coil domains
of the TACC gene. The resulting fusion proteins were found to promote tumor
growth (Singh et al. 2012).
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Taken together, the literature on TACC1 is not in agreement on a single
function for this protein. TACC1 may be involved in MAPK signaling pathways by
regulating the subcellular localization of phospho-ERK. Through its interactions
with YEATS4/GAS41, a member of the NuA4 acetyltransferase complex, TACC1
may also modulate histone acetylation and transcription. It has been implicated
as a regulator of mitotic exit through its interactions with Aurora B at the midbody
during cytokinesis, and as a regulator of RNA processing through its interactions
with LSM7 and SNRPG. The interaction of TACC1 with these RNA processing
factors is especially intriguing given the role of MBNL1 in RNA processing. LSM7
is a component of both the LSM1-7 complex and the LSM2-8 complex, which
mediate cytoplasmic mRNA decapping, and nuclear pre-mRNA splicing and
decay, respectively (Tharun 2009). SNRPG (small nuclear ribonucleoprotein G) is
a protein component of the snRNPs that make up the core spliceosome
machinery. It is therefore possible that downregulation of TACC1 by MBNL1
results in the dysregulation of splicing and stability of transcripts not directly
bound by MBNL1. It would also be interesting to test the effect of DBNL and
TACC1 on modulating the levels of the secreted factors that are upregulated in
MBNL1-knockdown cells. This might reveal a mechanistic link between MBNL1
and these downstream secreted factors.
4. MBNL1-dependent phenotypes and cancer progression
In this study, MBNL1 was found to suppress the invasion and transendothelial migration capacity of breast cancer cells. Both of these processes
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occur during metastatic progression, and programmed cell invasion is also critical
during normal development. In fact, MBNL1 has been reported to negatively
regulate endocardial cell invasion during chick heart development (Vajda et al.
2009). This illustrates that MBNL1 suppresses cell invasion during specific
normal developmental processes, and suggests breast cancer cells may be
commandeering this developmental function of MBNL1 to enhance their invasive
capacity. Another intriguing finding from the current study is that MBNL1
depletion results in a significant reduction in cell growth, both in culture and in
primary tumor growth assays (Figure 2.4A,B). This is consistent with MBNL1
acting as a promoter of primary tumor growth but a suppressor of metastasis.
MBNL1 levels are significantly correlated with distant metastasis-free survival in
breast cancer. Therefore, even if MBNL1 acts to promote primary tumor growth, it
could be associated with better clinical outcomes in breast cancer because it
suppresses cancer metastasis to distant organs. This finding is consistent with a
study that analyzed the outcomes of breast cancer patients that had node
positive disease and had very small or large primary breast tumors. Patients with
very small primary tumors had significantly increased breast cancer specific
mortality compared to those with large tumors (Wo et al. 2011). Therefore,
MBNL1 may act to suppress cancer cell invasion while simultaneously acting to
increase growth of the primary tumor. Given this, it is possible that downregulation of MBNL1 in small tumors might be an indicator of cancer
aggressiveness. It is also interesting to note that generally, MBNL1 acts as a
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promoter of tissue differentiation. Depletion of MBNL1 and MBNL2 leads to a
reversion to embryonic cell-like splicing patterns, and MBNL1 depletion leads to
an increased efficiency of induced pluripotent stem cell reprograming (Han et al.
2013; Lin et al. 2006). MBNL1 is also required for terminal differentiation of red
blood cells (Cheng et al. 2014). Together, these data are consistent with MBNL1
acting as a promoter of tissue differentiation. Therefore, it is interesting that in
breast cancer cells, depletion of MBNL1 leads to an increase in metastatic
capacity, as plasticity of gene expression can be advantageous during metastatic
progression.
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CHAPTER 6. METHODS AND MATERIALS
Animal Experiments
All mouse studies were conducted according to a protocol approved by the
Institutional Animal Care and Use Committee (IACUC) at the Rockefeller
University. For tail-vein colonization assays, 6-8 week old age matched female
NOD-scid mice were used. Cancer cells were engineered to stably overexpress
luciferase (Ponomarev et al. 2004), and these cells were injected into the tail vein
of each mouse. For systemic metastasis assays, 8 week old female athymic
mice were used, and cancer cells were injected into arterial circulation. The
location and number of cancer cells was monitored by bioluminescence in living
animals over times. Statistical significance was based on a one-tailed MannWhitney test. In vivo tumor growth assays were performed by injecting 5x105
cells mixed with 100ul of matrigel into bilateral mammary fat pats of 7 week old
female NOD-Scid mice. Tumor volume was assessed by caliper measurements.
Cell Culture
All cell lines were maintained at 37°C, 5% CO2. The 293LTV and MDAMB-231 and derivative cell lines were cultured in Dulbecco’s modified eagle
medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, 1mM
sodium pyruvate, 100 units/mL penicillin, 100 ug/mL streptomycin, and
amphotericin B (base media and supplements all Life Technologies). HUVECs
were obtained from ATCC and maintained in EGM-2 media (CC-3162 Lonza)
supplemented with 2% fetal bovine serum.
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RNAi-Mediated Gene Knockdown
Lentivirus was produced by transfecting 293LTV cells that had been
seeded in 6-well plates and allowed to become 60% confluent with 2ug pLKO.1
shRNA containing vector, 2 ug vector psPAX2 and 1 ug vector pMD2.G.
TransIT-293T (Mirus Bio) was used for transfection according to the
manufacturer’s protocol. Virus was harvested at 48 hours post-transfection and
passed through a 0.45um syringe filter to remove 293T cells.
Cancer cells were transduced by incubation with the lentivirus for 6 hours in the
presence of 8ug/mL polybrene. After transduction, media was changed to normal
growth media. Selection was started 48 hours after transduction by adding
puromycin to a final concentration of 1.5ug/ml. Cell were kept under selection for
48 hours.
For siRNA mediated gene knockdown, cells were seeded at 1.5x105 per
well in 6-well plates. 20 hours after seeding, cells were transfected with 90 pmol
of siRNA using lipofectamine 2000 (Life Technologies) according to the
manufacturer’s instructions.
Sequences targeted by shRNAs:
sh1MBNL1: 5’-GCCAACCAGAUACCCAUAAUA
sh2MBNL1: 5’-GCCUGCUUUGAUUCAUUGAAA
sh1TACC1: 5’-CCACGUCAUGUGGUCAGAAAU
sh2TACC1: 5’-GAAGGCAAAGUCGCGUUUAAU
shCTRL: 5’-CAACAAGAUGAAGAGCACCAA
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Sequences targeted by siRNAs:
siCTGF: 5’-UACCAGCAGAAAGGUUAGUAUCAUCAG
siFGFR1: 5’-ACACACCACCUACUUCUCCGUCAAUGU
si1LOXL2: 5’-CUGGAGCAGCACCAAGAGCCAGUCUUG
si2LOXL2: 5’-UUGGAGGACACAGAAUGUGAAGGAGAC
siMYL6-SE: 5’-AAGCGUUUGUGAGGCAUAUCCUGUCGG
siPICALM-SE: 5’-AACAAUGAAUGGCAUGCAUUUUCCACA
si1QSOX1: 5’-AAGCAACAUCAUCCUGGACUUCCCUGC
si2QSOX1: 5’-CUGGAGGAGAUUGAUGGAUUCUUUGCG
siSEC31A-SE: 5’-CAGCCGUAUCCCUUCGGAACAGGGG
siCTRL: 5’-CGUUAAUCGCGUAUAAUACGCGUAU
Retroviral and Lentiviral Mediated Protein Overexpression
Retrovirus was produced by transfecting 293T cells seeded in 6-well
plates with 2 ug of pBabe containing the ORF of interest, 2 ug Gag/Pol and 1 ug
VSV-G. Transfection was carried out using transIT-293T (Mirus Bio) according to
the manufacturer’s protocol. Virus was harvested 48 hours post-transfection and
passed through a 0.45um syringe filter to remove cells. For carboxy terminal flagtagged MBNL1 overexpression, target cells were transduced by incubation with
the retrovirus for 6 hours in the presence of 8 ug/mL polybrene. At this time,
media was changed to normal growth media. Selection was started 48 hours
after transduction by adding puromycin to a final concentration of 1.5 ug/mL or
hygromycin to a final concentration of 350 ug/mL. Puromycin selection was
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maintained for 48 hours, while hygromycin selection was carried out for 11-14
days.
Lentivirus was produced by transfecting 293LTV cells seeded in 6-well
plates with 2 ug pLX304 containing the ORF of interest with a carboxy-terminal
V5 tag, 2 ug vector psPAX2 and 1 ug vector pMD2.G. TransIT-293T (Mirus Bio)
was used to transfect the DNA per the manufacturer’s protocol. Virus was
harvested at 48 hours post-transfection and passed through a 0.45um syringe
filter to remove 293T cells. For c-terminal V5-tagged DBNL and TACC1
overexpression, target cancer cells were transduced by incubation with the
lentivirus for 6 hours in the presence of 8 ug/mL polybrene. After transduction,
media was changed to normal growth media. Selection was started 48 hours
after transduction by adding puromycin to a final concentration of 1.5 ug/ml. Cells
were typically kept under selection for 48 hours, or until cells that had not been
transduced as a control were all dead.
Transcriptomic Sequencing and Alternative Splicing Analysis
Whole transcriptome sequencing libraries were constructed using the ScriptSeq
v2 kit (Epicentre) per the manufacturer’s instructions. The input RNA was isolated
with a spin column based kit, including an on-column DNase treatment per the
manufacturer’s instructions (Norgen), and then depleted of rRNA using the RiboZero kit (Epicentre). The libraries were sequenced at the Rockefeller University
Genomics Resource center on a HiSeq2000 (Illumina). Reads were first trimmed
to remove linker sequences and low-quality bases, using cutadapt (v1.2.1).
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Tophat2 (v2.0.8) was then used to map the reads to the human transcriptome
(RefSeq transcriptome index, hg19). Cufflinks (v2.0.2) was then used to estimate
RPKM values and compare shControl and shMBNL1 samples.
For alternative splicing analysis, mapped reads from each of the two
MBNL1-targeting shRNA expressing MDA-231 cell lines were compared to the
shCTRL expressing cell line using MISO (v0.4.9) (Katz et al. 2010), in
conjunction with the provided annotations for skipped exons, to quantitate
modulations in alternative splicing events.
RT-PCR analysis of MISO-predicted transcript variants
Semi-quantitative real-time PCR was carried out by first isolating RNA and
synthesizing cDNA. This cDNA was used as the template for PCR to assess the
relative abundance of transcript isoforms. The PCR products were resolved on
1.5% or 2% agarose-TAE gels, as determined by the product sizes to be
separated. The PCR products were then visualized by ethidium bromide staining.
Quantitation of the bands was done using Image J software (NIH).
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Table 6.1 Primers used for RT-PCR analysis of MISO-predicted skipped exons

AKAP8L_SE_F! TGG AAC TTG GAA CTC TGG GA!
AKAP8L_SE_R! ACT CGG GGA TGA TGT TCT GG!
AMOTL1_SE_F! GTG AAT GGG GTT GAT TGT CCG !
AMOTL1_SE_R! AGG AAG TTT GGG GAG TGG AA!
CNOT10_SE_F! GCG AAA GCA GTG AAA CTT GC!
CNOT10_SE_R! GTC TGA TCC TTG GTC CTG CT!
DBNL_SE_F!

AGT GAA GGA CCC CAA CTC TG!

DBNL_SE_R!

ACG GCA TTG GTC TTC TGG TA!

DCTN1_SE_F!

CTG CAA GAA GAT CCG AAG GC!

DCTN1_SE_R!

CTT CGA GCT TCA AAC CCA GG!

FGFR1_SE_F!

AAG GAG GAT CGA GCT CAC TG!

FGFR1_SE_R!

CCA ATA TGG AGC TAC GGG GT!

HDLBP_SE_F!

GCT GTG GAG AGG CTA GAA GT!

HDLBP_SE_R!

TCT GCC CTT TCT TGC CAA TG!

HEATR2_SE_F! AGG ATT CGA AGA TGA CGC GA!
HEATR2_SE_R! CAC AAA CTC TGG CTC AGG TG!
INCENP_SE_F! CAG TGC AGA GGA ACC AGA TG!
INCENP_SE_R! GAT TCT CCA GGC GCT GC!
MTMR12_SE_F! AAA AGG AGT GGG TCA TGG GT!
MTMR12_SE_R! TCG TTG ATG TTT GAA GCG CA!
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MTX2_SE_F!

CTC GTT AAC TGC CGA GAG C!

MTX2_SE_R!

GCA TTT TCA GGC CAA GGT TC!

MYL6_SE_F!

AGA CAG TGG CCA AGA ACA AG!

MYL6_SE_R!

ATT CAC ACA GGG AAA GGC AC!

PICALM_SE_F!

ACC AAC AAC CGC TTG GAA TG!

PICALM_SE_R! AAA GGG GTT TGG AGG TCT CA!
PTPRF_SE_F!

CGA AGA CCA ACA GCA CAA GG!

PTPRF_SE_R!

GCA CGT AGG TGA CCT GGT AG!

RELA_SE_F!

AGC ACA GAT ACC ACC AAG AC!

RELA_SE_R!

CTT GGA AGG GGT TGT TGT TG!

SEC31A_SE_F! TCC GGG TTT CAT AAT GCA TGG !
SEC31A_SE_R! TGT TCA AAG CTG GAG GGT CA!
TCF3_SE_F!

GAC GGG GGT CTC CAC G!

TCF3_SE_R!

CAC TGT AGG AGT CGG GAG G!

ZNF512_SE_F!

GAT GTC TTC CAG ACT CGG TG!

ZNF512_SE_R!

TCG ACA TGA GAA GTA GCA GC!
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Quantitative Real-Time PCR
To carry out quantitative real time PCR (qRT-PCR), RNA was isolated using a
total RNA isolation kit, including an on-column DNase treatment (Norgen).
Synthesis of complementary DNA (cDNA) was carried out using the superscript
III reverse transcriptase kit (Life Technologies) using an oligodT for priming
unless otherwise specified. For each cDNA synthesis reaction, an equal mass of
total RNA reverse transcribed for all samples to be compared. Typically 1-2ug
per 20ul reaction was used. Synthesis was carried out per the manufactuer’s
instructions, including an RNase H digestion step. qRT-PCR was carried out in
technical quadruplicates, using fast syber green master mix (Applied Biosystems)
and fluorescence was monitored using a 7900HT Fast Real Time instrument
(Applied Biosystems). Data were analyzed using the delta delta Ct method.
Endogenous control transcript used for normalization are indicated in each figure.
Primers used for qRT-PCR
MBNL1: 5’-CTGCCCAATACCAGGTCAAC/5’-GGGGAAGTACAGCTTGAGGA
MBNL2: 5’-TGCCCAGCAGATGCAATTTA/5’-GGACCTACAGGGAAAGTGGG
DBNL: 5’-AAGGCTTCAGGTGCCAACTA/5’-GACACGGCATTGGTCTTCTG
TACC1: 5’-GCCTCAGCGAATCAGACAAG/5’-TGCCGGGTCTCTTCGTATTT
mCherry: 5’-CCTGTCCCCTCAGTTCATGT/5’-GTCCTCGAAGTTCATCACGC
TACC1-3UTR-1: 5’-GCCCTGGAAGAAACCCTAGA/
5’-AACCCAAACTCAGCAGCCTA
TACC1-3UTR-2: 5’-GGCCATTAACCCCAACATGG/
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5’-TGCATGGATTTGGGTTTGCC
TACC1-3UTR-3: 5’-CCCTTAAGAACCTGACCCCA/
5’-TCCTCATAACGGTCATGGCT
TACC1-3UTR-4: 5’-TCCAGCCAGTTACCCTTTCA/
5’-GGGCAGTTTACACTCCCTGT
TACC1-3UTR-5: 5’-GAAGACCCATCCCCTAGTGC/
5’-GCATGCTAAGAGGCACAGAA
DBNL-3UTR-1: 5’-CCCCTCTCAGACATGGCTTC/
5’-CACTGGGGGTCCTATTCCTG
DBNL-3UTR-2: 5’-TTGGCAGCAGGGAATTTGTC/
5’-TGCATCCCCACTTCCCATAG
HPRT1: 5’-ATGACCAGTCAACAGGGGAC/5’-CTGCATTGTTTTGCCAGTGTC
18S: 5’-AGCGAAAGCATTTGCCAAGA/5’-TATGGTCGGAACTACGACGG
Matrigel Invasion Assay
First, to induce invasiveness, cancer cells were serum-starved in media
containing 0.2% FBS for 20 hours. Cancer cells with siRNA-induced gene
knockdown were starved starting at 48 hours post siRNA transfection. The
starved cancer cells were seeded at 5 x 104 cells per well in matrigel coated
invasion chambers with 0.8um pore size (BD Biosciences) that had been preequilibrated in 0.2% FBS containing media. The cells were incubated for 20
hours at 37°C. After the cells had been allowed to invade for 20 hours, the
matrigel-coated inserts were washed with PBS. Using a q-tip the cells on the top
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side of each insert were scraped off. The inserts were fixed in 4%
paraformaldehyde for 15 minutes at 37°C, then cut out and mounted onto slides
using vectashield with DAPI (Vector Laboratories). The number of cells invaded
through the matrigel was quantified by imaging each insert using an inverted
fluorescence microscope (Zeiss Axiovert 40 CFL). Five images were taken per
insert at 10x magnification. ImageJ (NIH) was used to quantify the number of
invaded cells.
Trans-Endothelial Migration Assay
First, monolayers of HUVECs were prepared by seeding 5x104 HUVECs in EGM2 media on collagen coated HTS Fluoroblok with 0.3um pores transwell inserts
(Corning). After monolayer formation, cancer cells that had been serum-starved
in media containing 0.2% FBS for 20 hours and pulse labeled with cell tracker
green CMFDA dye (Life Technologies) were seeded on top of the HUVEC
monolayers at 5 × 104 cancer cells per well, in EGM2 media containing 0.2%
FBS. After 12 hours, the number of cancer cells migrating through the HUVEC
monolayer was quantified by imaging each insert using an inverted fluorescence
microscope (Zeiss Axiovert 40 CFL). Four images were taken per insert and
ImageJ (NIH) was used to quantify the number of cell migrated through the
HUVEC monolayer.
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Cell Proliferation Assay
To assay the effect of MBNL1 knockdown on cell proliferation, 2.5x104 cells were
seeded in 6-well plates in triplicate. After 5 days, the number of viable cells was
assessed using trypan blue, which is excluded from living cells.
Western Blotting
Whole cell lysate was prepared by washing trypsinized cells 2x with cold PBS,
resuspending the cell pellet in ice-cold RIPA buffer (25mM Tris-HCl pH 7.6,
150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with 1x complete
protease inhibitor cocktail (Roche) and incubating on ice for 20 minutes. The
lysate was sonicated to shear DNA and then cleared by spinning at 4°C in a
microcentrifuge at maximum speed for 15 minutes. The total protein
concentration of the resulting cleared lysate was determined using the BCA
assay method (Thermo Scientific). Equal amounts of total protein were run on 412% bis-tris NuPAGE gels in MOPS buffer (Life Technologies) under reducing
conditions. Proteins were transferred to 0.2um PVDF (Millipore) and blocked with
5% nonfat milk in PBS. Antibodies used in this study include custom made
polyclonal rabbit anti-MBNL1 (Yenzyme, raised to aa 363-378 of NP_066368),
anti-flag (Sigma F1804), anti-DBNL (Abcam ab86708) anti-TACC1 (Abcam
ab187358), anti-QSOX1 (Sigma SAB2700031), anti-LOXL2 (Abcam ab113201) .
The blots were incubated with horseradish peroxidase conjugated secondary
antibodies and developed using the ECL method (Thermo Scientific).
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High-Throughput Sequencing and Crosslinking Immunoprecipitation
(HITS-CLIP)
HITS-CLIP for endogenous MBNL1 was carried out as previously described
(Jensen and Darnell, 2008), with some modifications, as described in detail
below.
Crosslinking of cells
For each immunoprecipitation, ~5x106 cells were used. MDA-231 cells were
grown to sub-confluence before crosslinking and harvesting. Cells were rinsed 1x
with 5 mL cold PBS, the wash aspirated, then an additional 2 mL cold PBS was
added to just cover the cells. A Biorad genelinker was used to irradiate each
plate with 400mJ/cm2 UV (254nm) to crosslink RNA to proteins. Plates were
placed on ice and collected into a falcon tube by scraping. Cells were pelleted at
2000 rpm for 5 minutes at 4°C, and the PBS aspirated. Cells were resuspended
in 1mL cold PBS and transferred to a microcentrifuge tube. Cells were pelleted at
14,000 x g for 30 seconds at 4°C, and the PBS aspirated. The washed,
crosslinked cell pellets were immediately placed at -80°C.
Immunoprecipitation
For each immunoprecipitation,100ul of beads were used. Antibody-conjugated
beads were prepared by washing protein A dynabeads (Life Technologies) 1x
with PBS plus 0.02% tween-20, then resuspending beads in PBS plus 0.02%
tween-20 to 2x the original bead volume. To each 100ul of washed beads, either
15ug of rabbit IgG (Cell Signaling Technology) or 25ul of anti-MBNL1 antibody
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(0.6mg/mL)(Yenzyme) was added. The beads and antibodies were rotated at
room temperature for 30 minutes, then washed 3x with PBS plus 0.02% tween.
The crosslinked and frozen cell pellets were resuspend in 800uL cold low
salt wash buffer (1x phosphate buffered saline (PBS), 0.1% Sodium Dodecyl
Sulfate (SDS), 0.5% sodium deoxycholate, 0.5% IGEPAL CA-630) + 15ul RNasin
RNase inhibitor (40 units/ul, Promega) + 1x protease inhibitor cocktail (Roche
EDTA-free protease inhibitor tablets). To digest DNA and reduce viscosity of the
lysate, 30ul DNaseI RQ1(1 unit/ul, Promega) was added to the lysate and
incubated at 37°C for 5 minutes at 1000 rpm in a thermomixer. Lysate was
treated with high and low concentrations of RNase A. For the low RNase
treatment, RNase A (USB) was added to a final concentration of 30 pg/ul, while
for the high RNase treatment, RNAse A was added to a final concentration of
1500 pg/ul. After RNase addition, tubes were incubated at 37°C for 5 minutes,
then immediately placed on ice. Cell debris was then cleared from the lysate by
spinning at 16,000xg at 4°C for 20 minutes. The cleared supernatant was then
pipetted into clean tubes. The antibody-conjugated dynabeads were then added
to the cleared lysate, and the mixture rotated end-over-end at 4°C for 2 hours.
After the immunoprecipitation, the beads were collected on a magnet and the
supernatant removed. The beads were then washed in the following order (all
washes were ice cold): 2x low salt wash buffer, 2x high salt wash buffer (5X PBS,
0.1% SDS, 0.5% sodium deoxycholate, 0.5% IGEPAL CA-630), and finally 2x
PNK buffer (50mM Tris-HCl pH 7.4, 10mM MgCl2, 0.5% IGEPAL CA-630).
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Labeling and gel resolution of MBNL1-RNA complexes
In order to visualize the MBNL1 protein-RNA complexes, a radioactively labeled
RNA oligo was ligated to the immunoprecipitated protein-RNA complexes. To
prepare the labeled oligo the 3’ RNA linker oligo 5’-GUG UCA GUC ACU UCC
AGC GG-puromycin was 5’ 32P labeled using T4 PNK (NEB) and γ- 32P ATP
(Perkin Elmer). The 3’ puromycin is added to the oligo to block unwanted ligation
products at later steps in the protocol. After end labeling, excess nucleotides
were removed from the reaction by running it through a G-25 sephadex spin
column (GE life sciences). To prepare the RNA in the immunoprecipitated
protein-RNA complexes for ligation, the immunoprecipitation was treated with calf
alkaline intestinal phosphatase (CIP) (Roche) to dephosphorylate the RNA ends.
After CIP treatment, the immunoprecipitations were washed in the following
order, (all washes were ice cold): 1x with PNK buffer, 1x with PNK + EGTA buffer
(50mM Tris-HCl pH 7.4, 20mM EGTA, 0.5% IGEPAL CA-630), 2x with PNK
buffer. The 32P-labled RNA oligo was then ligated to the protein complexes by
adding the following to the beads after removing all of the last wash from the
previous step: 5ul 10x T4 RNA ligase buffer, 5ul BSA (1mg/mL), 5ul 10mM ATP,
1.25ul T4 RNA ligase (5 units/ul) (Fermentas), 1.25ul RNasin, 6.25ul 32P-labeled
3’ linker oligo (7.5 pmol total), H2O to 50ul. Reactions were incubated at 16°C for
1 hour in a thermomixer with shaking at 1000 rpm for 30 seconds every 15
minutes. After 1 hour, 48 pmol of the 3’ linker oligo (5’ phosphorylated with cold
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ATP) was added to the ligation mixture and the mixture was incubated at 16°C
for 16 hours.
After ligation of the 3’ linker oligo, the immunoprecipitations were washed
in the following order (all washes were ice cold): 1x with low salt wash buffer, 1x
with high salt wash buffer, 3x with PNK buffer. The 5’ ends of the protein-RNA
complexes were then phosphorylated using T4 PNK, and then washed 3X with
ice cold PNK buffer. These labeled protein-RNA complexes were then eluted
from the beads by resuspending the beads in 40ul of 1x NuPAGE loading buffer
(Life Technologies) and heating at 70 deg C in a thermomixer at 1000 rpm for 10
minutes. The beads were immediately collected on a magnet, and the eluted
complexes were run on a 4-12% bis-tris NuPAGE gel (Life Technologies) in 1x
MOPS running buffer (Life Technologies) at 150 volts in the cold room. The
complexes were then transferred onto BA-85 nitrocellulose (Whatman) in cold 1x
NuPAGE transfer buffer with 10% methanol at 100 volts in the cold room. To
visualize the RNA-protein complexes, the membrane was then exposed to film
and the film was developed.
In order to size select the RNA to make the HITS-CLIP library, the bands
migrating at ~55-70 kDa in the low RNase treated lanes were cut from the
nitrocellulose. This is because MBNL1 alone migrates at ~40 kDa, and the
average molecular weight of 50 nucleotide long RNA, the minimum size for
informative sequencing analysis, is ~15 kDa. The nitrocellulose was cut into
smaller pieces and treated with proteinase K and then phenol chloroform
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extracted to digest the protein and isolate the RNA. The aqueous layer was
precipitated by adding ethanol:isopropanol (1:1), glycoblue, and sodium acetate,
then incubating overnight at -20°C. The RNA pellet was washed 2x with 75%
ethanol then air dried, then resuspended in 5.9ul H2O.
5’ linker ligation, cDNA synthesis and PCR amplification MBNL1 bound RNA
A 5’ linker RNA oligo was then ligated to the isolated RNA by adding the
following components to the RNA: 1ul 10x T4 RNA ligase buffer, 1ul BSA
(0.2mg/mL), 1ul 10mM ATP, 0.1ul T4 RNA ligase, 1ul of the 5’ linker RNA oligo at
20 pmol/ul (5’-AGGGAGGACGAUGCGG). The ligation mixture was incubated at
16°C overnight in a PCR tube in a thermocycler. The ligation reaction was then
treated with DNase to remove any residual DNA. This mixture was then phenol
chloroform extracted and the RNA recovered from the aqueous layer by
ethanol:isopropanol precipitation as above. The RNA pellet was washed 2x with
75% ethanol and then air dried. The RNA pellet was resuspended in 10ul H2O.
From this RNA, cDNA was synthesized by adding the following to 8ul of
the resuspended RNA: 2ul DP3 primer at 5pmol/ul (5’CCGCTGGAAGTGACTGACAC), 3ul 3mM dNTPs. As a control for DNA
contamination, a parallel cDNA synthesis without the reverse transcriptase was
done with the 2ul remaining of the resuspended RNA. The mixtures were
incubated at 65°C for 5 minutes, then at 4°C for 1 minute. To this, the following
was added: 1ul 0.1 M DTT, 4ul 5x superscript reverse transcriptase buffer, 1ul
RNasin, 1ul superscript III (Life Technologies) or 1ul H2O (for the no reverse
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transcriptase control reactions). The reactions were then incubated at 50°C for 45
minutes, then 55°C for 15 minutes, then 90°C for 5 minutes, then placed on ice.
This cDNA was then amplified by PCR using accuprime Pfx supermix (Life
Technologies and the primer pair: DP5: 5’-AGGGAGGACGATGCGG/
DP3: 5’-CCGCTGGAAGTGACTGACAC. The optimal number of cycles was
determined by running 22-30 cycles of the follow program: 1. 95°C 2 min 2. 95°C
20 sec 3. 58°C 30 sec 4. 68°C 20 sec. repeat 2-4 for 22-20 cycles 5. 68°C 5 min.
Formamide loading dye (2x solution: 95% deionized formamide, 5% 100mM
EDTA pH 7.5, bromophenol blue for tracking) was added to the resulting PCR
products were run on a 10% TBE-polyacrylamide urea gel and visualized by
post-staining with SYBR gold (Life Technologies). Amplisize molecular ruler
(Biorad) was run alongside the PCR products as a size standard. PCR products
running at ~90-140 basepairs were cut from the gel and the DNA isolated from
the gel slice using the Qiagen gel extraction kit per instructions for extracting
DNA fragments from polyacrylamide gels. DNA was eluted from the spin column
with 30ul EB.
Next, this eluted DNA was further PCR amplified and Illumina sequencing
compatible sequences added. To each PCR tube, the following was added: 27ul
Accuprime Pfx supermix (Life Technologies), 0.5ul 20uM DSFP5 (5'AATGATACGGCGACCACCGACTATGGATACTTAGTCAGGGAGGACGATGCG
G), 0.5ul 20uM DSFP3(5'CAAGCAGAAGACGGCATACGACCGCTGGAAGTGACTGACAC), 3ul of DNA
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isolated in previous step. The reactions were then cycled according to the
following program: 1. 95°C 2 min 2. 95°C 20 sec 3. 58°C 30 sec 4. 68°C 40 sec.
repeat 2-4 for 6-10 cycles 5. 68°C 5 min. The products were run on a 2%
metaphor agarose-TBE gel and visualized by ethidium bromide staining. PCR
products running between 150-170 basepairs were gel extracted using the
Qiagen gel extraction kit. DNA was eluted from the spin column with 30ul EB.
Library sequencing and computational analysis
The biological duplicate MBNL1 HITS-CLIP libraries were sequenced at
the Rockefeller University Genomics Resource Center on an Illumina HiSeq 2000
instrument with 50 bp single-end run length. The sequencing reads were first
trimmed to remove linker sequences and low-quality bases, using cutadapt
(v1.2.1) with parameters -q 15 and -m 25. The Resulting reads were then aligned
to the human genome (build hg19) using bowtie2 (v2.1.0). The analytical
package CIMS (Zhang et al. 2011) was then used to identify CLIP peaks in each
of the biological replicates (FDR<10%). The peaks from the two replicates were
then overlapped (intersectBed) to generate a high-confidence list of MBNL1
binding sites. Sequences were extracted and analyzed for motif discovery using
ChIPseeqer (Giannopoulou and Elemento 2011). Briefly, a randomized
background set was generated using a 1st-order Markov Model to control for
length and dinucleotide frequency in the real binding sites. The resulting 'real'
and 'scrambled' sequences were then analyzed using FIRE (Elemento et al.
2007) to identify the best representation of the MBNL1 binding site.
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Transcript Stability Assays
For the alpha-amanitin microarray data, MDA-231 MBNL1 knockdown or
control cells were treated with 10ug/mL alpha-amanitin (Sigma). Nine hours after
alpha-amanitin addition, RNA was isolated from the cells using a total RNA
isolation kit with on-column DNase treatment (Norgen). RNA was labeled using
the TargetAmp nano labeling kit according to the manufactuer’s protocol
(Epicentre), and hybridized to Illumina beadchip arrays. Lumi package (R) was
used to normalize and compare Illumina HT12 Beadchip raw signals for
shControl and sh1MBNL1 samples at 0 and 9 hours post alpha-amanitin
treatment. The difference between the sh1MBNBL1/shControl logFCs were used
as a measure of stability. To discretize the input values, transcripts with logFC
difference of less than -0.1 were labeled as "destabilized". The computational tool
TEISER, in non-discovery mode, was then used to assess the stability of
MBNL1-bound transcripts in this dataset (as described in Goodarzi et al. 2014).
Cells were seeded at 2x105 per well in 6-well plates. 18 hours after
seeding, 5,6- Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB)(Sigma) was
added to the cells to a final concentration of 100μM. RNA was isolated at 0, 2, 4,
6 and 8 hours after DRB addition using a total RNA isolation kit with on-column
DNase treatment (Norgen). Relative levels of the transcripts of interest were
assessed by qRT-PCR, using 18S as the endogenous control. Half-life
calculations were done using the formula t1/2=ln2/kdecay, where the decay constant
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was determined by plotting the data on a semilog scale and using non-linear
regression to find the best fit line (Graphpad Prism).
Poly(A) Tail Length Assay
Length of the poly(A) tails was measured as described in (Janicke et al. 2012).
Total RNA was isolated using a spin-column based total RNA extraction kit,
including an on-column DNase-treatment step (Norgen). An anchor primer (5’GCGAGCTCCGCGGCCGCGTTTTTTTTTTTT ) was annealed to poly(A)
sequences by mixing the following in a PCR tube: 1ul 100uM ePAT anchor
primer, 1ug total RNA, H2O to a final volume of 8ul. This was incubated at 80°C
for 5min, cooled to 25°C, and then Klenow polymerase was used to fill in the
overhang by adding the following to the mix: 1ul Klenow polyermerase (-exo)
(5U/ul, NEB), 4ul 5X superscript III buffer, 1ul 0.1M DTT, 1ul 10mM dNTPs, 4ul
H2O, 1ul RNase out. The mixture was then incubated at 25°C for 1 hour, then the
Klenow inactivated by incubating at 80°C for 10 min, then cooled to 55°C. While
holding at 55°C, 1ul superscript III reverse transcriptase (200U/ul, Life
Technologies) was added and then the mixture incubated at 55°C for another
hour and the enzyme heat inactivated by incubating at 80°C for 10 min.
The poly(A) tail length of each transcript of interest was then assessed by using
this 3’ tagged cDNA as the template from which to PCR amplify the region
between the anchor primer specific sequence and a sequence 100-300
nucleotides upstream from the 3’ end of, and specific to, the transcript of interest.
Oligonucleotides used for poly(A) tail length assay:
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Universal reverse primer: 5’-GCGCCGGCGCCTCGA
DBNL-1 forward: 5’-TGTGTGCCTCAACTGATTCTGACTTCAGG
DBNL-2 forward: 5’-CGGCTCACTCGATGCCTGCAGG
TACC1-1 forward: 5’-GCGTTGACTACTGCTATCAGGATTGTGTTGTG
TACC1-2 forward: 5’-GGGTGCCATGAAGTGTGTGAGGAGC
PCR was carried out by mixing the following: 2.5ul 10x reaction buffer, 0.5ul
10mM dNTPs, 1ul MgSO4, 1ul 5uM gene specific forward primer (see above),
1ul 5uM universal reverse primer, 1ul 3’ tagged cDNA (as synthesized in the first
step), 0.1ul hi fidelity platinum taq (Life Technologies), 17.9ul H2O. The reactions
were cycled using the following protocol: 1. 94°C 2 min 2. 94°C 15 sec 3. 58°C
30 sec 4. 68°C 35 sec. repeat 2-4 x 30. 5. 68°C 5 min. The resulting PCR
products were resolved by running on a 2% agarose-TAE gel and visualized by
ethidium bromide staining.
MBNL1, DBNL and TACC1 Expression Correlation with Clinical Outcome
To test the correlation of MBNL1, MBNL2, MBNL3 and TACC1 expression levels
with clinical outcome in breast cancer, the kmplot meta data set was used
(Gyorffy et al. 2010). Expression levels of the genes were divided into high and
low based on the median expression level, and a censoring threshold of 10 years
was set. P-values were based on the Mantel-Cox log-rank test. DBNL expression
correlation with clinical outcome in breast cancer was assessed by qRT-PCR in a
set of 48 staged breast tumor samples, using beta-actin as an endogenous
control (Origene, breast cancer panel 3).
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Conditioned Media Preparation
Conditioned media for assessment by Western blotting was prepared by seeding
5x104 cancer cells per well in 24 well plates. After 18 hours, the cells were
washed twice with PBS, and 0.2mL of serum free DMEM complete media was
added (DMEM media supplemented with 2mM L-glutamine, 1mM sodium
pyruvate, 100 units/mL penicillin, 100 ug/mL streptomycin, and amphotericin B).
After 24 hours, the media was harvested and spun at 5x103 rpm for 10 minutes to
pellet any cells. The supernatant was removed and equal volumes were assayed
by Western blotting or ELISA. Extracellular CTGF levels in conditioned media
from MDA-231 cells with MBNL1 knockdown or control cells were quantified
using a CTGF ELISA kit (PeproTech). Conditioned media for treatment of cancer
cells in transwell invasion assays was prepared in the same manner.
SILAC-Mass Spectrometry
Proteins from MDA-231 MBNL1 knockdown cells were isotopically labeled by
growing in media supplemented with isotopically labeled [13C6]-L-lysine and
[13C6,15N4]-L-Arginine by passaging cells for ten days in DMEM-flex media
supplemented with the labeled amino acids along with 10% dialyzed FBS, Lglutamine, penicillin, streptomycin and amphotericin (Life Technologies). In
parallel, MDA-231 cells expressing a control shRNA were passaged identically,
but in media containing normal lysine and arginine. To harvest secreted proteins,
plates were washed twice in PBS, and media containing all of the above
components except FBS was added. After 20 hours, the media from the plates
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was harvested and equal volumes were mixed. The proteins were separated by
SDS-PAGE, and bands were excised and subjected to mass spectrometry.
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